Insulin-producing cells

By controlling the differentiation process of pluripotent stem cells and using FGFR1 inhibitor culture medium, high-purity insulin and glucagon-producing cells were prepared, solving the problem of low cell purity in existing technologies and achieving highly efficient cell therapy effects, especially in the treatment of diabetes, such as glycemic control and reduction of the risk of hypoglycemia.

CN112867787BActive Publication Date: 2024-11-22ORIZURU THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980061019.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-09-19
Filing Date
2019-09-18
Publication Date
2024-11-22
Estimated Expiration
2039-09-18

AI Technical Summary

Technical Problem

Existing technologies struggle to efficiently induce the production of high-purity insulin-producing cells and glucagon-producing cells from pluripotent stem cells, resulting in low cell purity after transplantation.

Method used

By controlling the differentiation process of pluripotent stem cells, ensuring a high proportion of NKX6.1 positive cells and a low proportion of Ki67 positive cells in insulin-producing cells, and combining this with an FGFR1 inhibitor culture medium, high-purity insulin-producing cells were prepared. Subsequently, these cells were matured in vivo to improve cell purity and function.

Benefits of technology

This technology enables the efficient induction of high-purity insulin and glucagon-producing cells in vivo, improving the efficacy of cell therapy, particularly in the treatment of diabetes, by effectively controlling blood glucose levels and reducing the risk of hypoglycemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112867787B_ABST
    Figure CN112867787B_ABST
Patent Text Reader

Abstract

The present invention aims to provide a new technology capable of efficiently inducing / producing endocrine cells from pluripotent stem cells. An insulin-producing cell, wherein the insulin-producing cell comprises insulin-positive and NKX6.1-positive cells at a ratio of more than 30%, and insulin-positive and NKX6.1-negative cells at a ratio of more than 15%.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an insulin-producing cell capable of efficiently inducing / producing endocrine cells called pancreatic β cells or pancreatic α cells that secrete hormones, and a production method and use thereof. Background Art

[0002] Research is being advanced on inducing endocrine cells called pancreatic β cells or pancreatic α cells that secrete hormones from pluripotent stem cells such as artificial pluripotent cells or embryonic stem cells (ES cells) and applying them to the treatment of diabetes. It is known that when pluripotent stem cells are differentiated, cells with different characteristics appear at different stages of differentiation (WO 2009 / 012428, WO 2016 / 021734). For example, this differentiation stage can be roughly divided into pluripotent stem cells, embryonic endoderm cells, gastrointestinal cells, posterior foregut cells, pancreatic precursor cells, endocrine precursor cells, insulin-producing cells, and pancreatic β cells in the order of relative undifferentiation.

[0003] So far, technologies for inducing differentiation from pluripotent stem cells into endocrine cells including insulin-positive cells have been developed and reported. For example, in Non-Patent Documents 1 and 2, methods for producing insulin-producing cells differentiated from pluripotent stem cells are described, wherein the insulin-producing cells contain insulin-positive and NKX6.1-positive cells at a ratio of 30% or more and insulin-positive and NKX6.1-negative cells at a ratio of 15% or less.

[0004] In addition, to date, a technique for producing endocrine cells by inducing differentiation from pluripotent stem cells to pancreatic progenitor cells and then transplanting them into a living body and maturing them has been reported. For example, in Non-Patent Document 3, a method for producing endocrine cells including insulin-positive cells and glucagon-positive cells by transplanting pancreatic progenitor cells differentiated from pluripotent stem cells into mice and maturing them has been described.

[0005] However, the ratio of endocrine cells produced by the above methods is not high enough, and a method for efficiently inducing / producing endocrine cells from pluripotent stem cells is still desired in this field.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent Document 1: WO 2009 / 012428

[0009] Patent document 2: WO 2016 / 021734

[0010] Non-patent literature

[0011] Non-patent literature 1: Rezania A. et al., Nat Biotechnol. 2014; 32: 1121-33.

[0012] Non-patent document 2: Felicia W. Pagliuca et al., Cell. 2014 Oct 9; 159(2): 428-439.

[0013] Non-patent document 3: Robert T et al., Stem Cell Reports. 2018 Mar 13; 10(3): 739-750. Summary of the invention

[0014] Problems to be solved by the invention

[0015] An object of the present invention is to provide a new technology capable of efficiently inducing / producing islet-like cells containing insulin-positive cells and glucagon-positive cells at a certain ratio from pluripotent stem cells.

[0016] Means for solving problems

[0017] In the past, the focus has been on how to increase the proportion of insulin-positive and NKX6.1-positive cells and how to mature them. The inventors and others have conducted intensive research to solve the above-mentioned problems. As a result, they have found that by making the cells other than the above-mentioned cells a predetermined proportion, islet-like cells with high purity can be efficiently induced / produced in vivo. Differentiation induces insulin-producing cells that are not as mature as insulin-producing cells produced by previous technologies, specifically, insulin-producing cells that do not express maturation indicators such as MafA, and contain many cells that become the origin of glucagon-producing cells. People are worried that cells with low maturity will obtain cells with low purity after transplantation, but by combining the technology of reducing Ki67-positive cells with proliferation ability to the limit, islet-like cells have been successfully matured in vivo while maintaining high purity.

[0018] The present invention provides an optimal technology for achieving cell therapy of pancreatic islets because it can efficiently induce pancreatic islet-like cells with high purity within the shortest production period.

[0019] The present invention is based on these new findings and includes the following inventions.

[0020] [1] An insulin-producing cell (population), comprising 30% or more of insulin-positive and NKX6.1-positive cells and more than 15% of insulin-positive and NKX6.1-negative cells.

[0021] [2] The insulin-producing cell (population) according to [1], wherein the expression level of the MafA gene or its gene product is lower than the expression level of the MafA gene or its gene product in pancreatic islets.

[0022] [3] The insulin-producing cell (population) according to [1] or [2], wherein the insulin-producing cell (population) comprises Ki67-positive cells at a ratio of less than 3%.

[0023] [3-1] The insulin-producing cell (population) according to [1] or [2], wherein the insulin-producing cell (population) contains Ki67-positive cells at a ratio of less than 1%.

[0024] [4] The insulin-producing cell (population) according to any one of [1] to [3-1], wherein the insulin-producing cell (population) comprises glucagon-positive and insulin-negative cells at a ratio of less than 3%.

[0025] [5] The insulin-producing cell (population) according to any one of [1] to [4], wherein the insulin-producing cell (population) exhibits a glucose-stimulated insulin secretion (GSIS) response.

[0026] [6] The insulin-producing cell (population) according to any one of [1] to [5], wherein the insulin-producing cell (population) comprises chromogranin A-positive cells at a ratio of more than 45%.

[0027] [6-1] The insulin-producing cell (population) according to any one of [1] to [5], wherein the insulin-producing cell (population) comprises chromogranin A-positive cells at a ratio of more than 80%.

[0028] [6-2] The insulin-producing cell (population) according to any one of [1] to [5], wherein the insulin-producing cell (population) comprises chromogranin A-positive cells at a ratio of more than 85%.

[0029] [6-3] The insulin-producing cell (population) according to any one of [1] to [5], wherein the insulin-producing cell (population) comprises chromogranin A-positive cells at a ratio of more than 90%.

[0030] [6-4] The insulin-producing cell (population) according to any one of [1] to [5], wherein the insulin-producing cell (population) comprises chromogranin A-positive cells at a ratio of more than 93%.

[0031] [7] The insulin-producing cell (population) according to any one of [1] to [6-4], wherein the insulin-producing cell (population) comprises alkaline phosphatase-positive pluripotent stem cells at a ratio of less than 0.01%.

[0032] [7-1] The insulin-producing cell (population) according to any one of [1] to [7], wherein the insulin-producing cell (population) differentiates into islet-like cells in vivo.

[0033] [7-2] The insulin-producing cell (population) according to [7-1], wherein the islet-like cells contain chromogranin A-positive cells at a ratio of 50% or more.

[0034] [7-2-1] The insulin-producing cell (population) according to [7-1], wherein the islet-like cells contain chromogranin A-positive cells at a ratio of 95% or more.

[0035] [7-3] The insulin-producing cell (population) according to any one of [7-1] to [7-2-1], wherein the islet-like cells contain Ki67-positive cells at a ratio of less than 3%.

[0036] [7-3-1] The insulin-producing cell (population) according to any one of [7-1] to [7-2-1], wherein the islet-like cells contain Ki67-positive cells at a ratio of less than 1%.

[0037] [7-4] The insulin-producing cell (population) according to any one of [7-1] to [7-3-1], wherein the islet-like cells contain glucagon-positive and insulin-negative cells at a ratio of 10% or more.

[0038] [7-5] The insulin-producing cell (population) according to any one of [7-1] to [7-4], wherein the islet-like cells have an insulin secretion function in response to hypoglycemia.

[0039] [8] A drug comprising the insulin-producing cell according to any one of [1] to [7-5].

[0040] [9] The drug according to [8], wherein the insulin-producing cell (population) is contained in a device.

[0041]

[10] The drug according to [8] or [9], wherein the insulin-producing cells (population) are dispersed in a hydrogel.

[0042]

[11] The drug according to any one of [8] to

[10] , which is used by transplantation into a living body.

[0043]

[12] The drug according to any one of [8] to

[11] , which is used by subcutaneous transplantation.

[0044]

[13] The drug according to any one of [8] to

[12] , which is used for the treatment of diabetes.

[0045]

[14] The drug according to any one of [8] to

[12] , which is used to improve and / or maintain the control of the patient's fasting and postprandial glucose levels.

[0046]

[15] The drug according to any one of [8] to

[12] , which is used to reduce the risk of hypoglycemia in a diabetic patient.

[0047]

[16] The drug according to any one of [8] to

[12] , which is used in a method for inducing differentiation of islet-like cells (populations) in vivo.

[0048]

[17] The drug according to

[16] , wherein the islet-like cells (population) induced to differentiate in vivo contain chromogranin A-positive cells at a ratio of 50% or more.

[0049] [17-1] The drug according to

[16] , wherein the islet-like cells (population) induced to differentiate in vivo contain chromogranin A-positive cells at a ratio of 95% or more.

[0050]

[18] The drug according to any one of

[16] to [17-1], wherein the islet-like cells (population) induced to differentiate in vivo contain Ki67-positive cells at a ratio of less than 3%.

[0051]

[18] The drug according to any one of

[16] to [17-1], wherein the islet-like cells (population) induced to differentiate in vivo contain Ki67-positive cells at a ratio of less than 1%.

[0052]

[19] The drug according to any one of

[16] to

[18] , wherein the islet-like cells (population) induced to differentiate in vivo contain glucagon-positive and insulin-negative cells at a ratio of 10% or more.

[0053]

[20] The drug according to any one of

[16] to

[19] , wherein the islet-like cells (population) induced to differentiate in vivo have an insulin secretion effect in response to hypoglycemia.

[0054]

[21] A method for producing insulin-producing cells (groups), wherein the insulin-producing cells (groups) contain insulin-positive and NKX6.1-positive cells at a ratio of more than 30%, and contain insulin-positive and NKX6.1-negative cells at a ratio of more than 15%; the method for producing insulin-producing cells (groups) comprises the following steps: culturing pluripotent stem cells in the presence of a low dose of activin A to produce embryonic endoderm cells; and culturing endocrine precursor cells in a culture medium containing an FGFR1 inhibitor to produce the insulin-producing cells (groups).

[0055]

[22] A method for producing islet-like cells (groups), the method comprising transplanting insulin-producing cells (groups) into a living body and inducing differentiation into islet-like cells (groups), wherein the insulin-producing cells (groups) contain insulin-positive and NKX6.1-positive cells at a ratio of more than 30%, and contain insulin-positive and NKX6.1-negative cells at a ratio of more than 15%.

[0056]

[23] A method for treating diabetes, comprising transplanting insulin-producing cells (groups) into a living body and inducing differentiation into islet-like cells (groups), wherein the insulin-producing cells (groups) contain insulin-positive and NKX6.1-positive cells at a ratio of more than 30%, and contain insulin-positive and NKX6.1-negative cells at a ratio of more than 15%.

[0057]

[24] A method for improving and / or maintaining control of a patient's fasting and postprandial glucose levels, the method comprising transplanting insulin-producing cells (populations) into a living body and inducing differentiation into islet-like cells (populations), wherein the insulin-producing cells (populations) contain more than 30% insulin-positive and NKX6.1-positive cells, and more than 15% insulin-positive and NKX6.1-negative cells.

[0058]

[25] A method for reducing the risk of hypoglycemia in diabetic patients, the method comprising transplanting insulin-producing cells (populations) into a living body and inducing differentiation into islet-like cells (populations), wherein the insulin-producing cells (populations) contain insulin-positive and NKX6.1-positive cells at a ratio of more than 30%, and contain insulin-positive and NKX6.1-negative cells at a ratio of more than 15%.

[0059]

[26] The insulin-producing cell (population) according to any one of [1] to [7-5], wherein the insulin-producing cell (population) is used for a method for treating diabetes.

[0060]

[27] The insulin-producing cell (population) according to any one of [1] to [7-5], wherein the insulin-producing cell (population) is used to improve and / or maintain the control of a patient's fasting and postprandial glucose levels.

[0061]

[28] The insulin-producing cell (population) according to any one of [1] to [7-5], wherein the insulin-producing cell (population) is used in a method for reducing the risk of hypoglycemia in a diabetic patient.

[0062]

[29] The insulin-producing cell (population) according to any one of [1] to [7-5], wherein the insulin-producing cell (population) is used in a method for inducing differentiation into islet-like cells (population) in vivo.

[0063]

[30] The insulin-producing cell (population) according to any one of

[26] to

[29] , wherein the insulin-producing cell (population) is housed in a device.

[0064]

[31] The insulin-producing cell (population) according to any one of

[26] to

[30] , wherein the insulin-producing cell (population) is dispersed in a hydrogel.

[0065]

[32] The insulin-producing cell (population) according to any one of

[26] to

[31] , wherein the insulin-producing cell (population) is used by transplantation into a living body.

[0066]

[33] The insulin-producing cell (population) according to any one of

[26] to

[32] , wherein the insulin-producing cell (population) is used by subcutaneous transplantation.

[0067]

[34] The insulin-producing cell (population) according to

[29] , wherein the islet-like cells (population) differentiated and induced in vivo contain chromogranin A-positive cells at a ratio of 50% or more.

[0068] [34-1] The insulin-producing cell (population) according to

[29] , wherein the islet-like cells (population) differentiated and induced in vivo contain chromogranin A-positive cells at a ratio of 95% or more.

[0069]

[35] The insulin-producing cell (population) according to

[29] , wherein the islet-like cells (population) differentiated and induced in vivo contain Ki67-positive cells at a ratio of less than 3%.

[0070] [35-1] The insulin-producing cell (population) according to

[29] , wherein the islet-like cells (population) differentiated and induced in vivo contain Ki67-positive cells at a ratio of less than 1%.

[0071] [35-2] The insulin-producing cell (population) according to

[29] , wherein the islet-like cells (population) induced to differentiate in vivo contain glucagon-positive and insulin-negative cells at a ratio of 10% or more.

[0072]

[36] The insulin-producing cell (population) according to

[29] , wherein the islet-like cell (population) induced to differentiate in vivo has an insulin secretion function in response to hypoglycemia.

[0073]

[37] A use of the insulin-producing cell (population) according to any one of [1] to [7-5], wherein the insulin-producing cell (population) is used to manufacture a drug for treating diabetes.

[0074]

[38] A use of the insulin-producing cell (group) according to any one of [1] to [7-5], wherein the insulin-producing cell (group) is used to manufacture a drug for improving and / or maintaining the control of a patient's fasting and postprandial glucose levels.

[0075]

[39] A use of the insulin-producing cell (population) according to any one of [1] to [7-5], wherein the insulin-producing cell (population) is used to manufacture a drug for reducing the risk of hypoglycemia in diabetic patients.

[0076] This specification includes the contents described in the specification and / or drawings of Japanese Patent Application No. 2018-175465 which is the basis for the priority of this application.

[0077] All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if fully set forth.

[0078] Effects of the Invention

[0079] According to the present invention, a new technology capable of efficiently inducing and producing endocrine cells from pluripotent stem cells can be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0080] Figure 1 The graph shows the results of flow cytometry measurement of the expressions of insulin (INS), NKX6.1, glucagon (GCG), and Ki67 in a prototype of insulin-producing cells, insulin-producing cells, and human pancreatic islets.

[0081] Figure 2 The results of measuring the expression levels of each gene of insulin (INS), glucagon (GCG), MafA, and UCN3 in the prototype of insulin-producing cells, insulin-producing cells, and human pancreatic islets by quantitative PCR are shown.

[0082] Figure 3 The graph shows the colony numbers of iPS cells maintained in an undifferentiated state in insulin-producing cells prepared by adding 30 (0.005%) cells, 6 (0.001%) cells, and 0 cells of iPS cells maintained in an undifferentiated state.

[0083] Figure 4 The figure shows phase contrast microscopic images of cell aggregates obtained by thawing cryopreserved insulin-producing cells and then culturing them three-dimensionally for 4 days.

[0084] Figure 5 The results of flow cytometric measurement of the expressions of INS, NKX6.1, and Ki67 in insulin-producing cells before cryopreservation and in insulin-producing cells after cryopreservation / thawing are shown.

[0085] Figure 6 The results of measuring the human C-peptide concentration in the blood after glucose loading in diabetic mice transplanted with insulin-producing cells and non-diabetic mice not transplanted with insulin-producing cells are shown.

[0086] Figure 7 The present invention shows the results of measuring the blood human C-peptide concentration and blood glucagon concentration after administration of glargine insulin in diabetic mice transplanted with insulin-producing cells and non-diabetic mice not transplanted with insulin-producing cells.

[0087] Figure 8 The graph shows the results of flow cytometry measurement of the expressions of insulin, NKX6.1, glucagon, and chromogranin A in subcutaneously transplanted insulin-producing cells.

[0088] Fig. 9 The results of immunohistochemical staining for insulin and glucagon in subcutaneously transplanted insulin-producing cells are shown. Green: insulin-positive cells. Red: glucagon-positive cells. DETAILED DESCRIPTION

[0089] 1. Terminology

[0090] Hereinafter, terms used in this specification will be described.

[0091] In this specification, "about" refers to a fluctuation value of plus or minus 25%, 20%, 10%, 8%, 6%, 5%, 4%, 3%, 2% or up to 1% relative to a reference value. Preferably, the term "about" or "approximately" means a range of plus or minus 15%, 10%, 5% or 1% relative to a reference value.

[0092] In the present specification, the numerical range defining the present invention includes numerical values ​​that are considered to be substantially the same as the lower limit and the upper limit even without the description of "about".

[0093] In this specification, "comprise(s) or comprising" means including but not limited to the elements following the term. Therefore, it implies the inclusion of the elements following the term, but does not imply the exclusion of any other elements.

[0094] In this specification, "consist(s) of or consisting of" means including and limited to all the elements following the term. Therefore, the term "consist(s) of" means that the listed elements are essential or necessary, and there are substantially no other elements.

[0095] In this specification, "not using feeder cells" means that feeder cells are substantially not contained, and a medium preconditioned by culturing feeder cells is not used. Therefore, the medium does not contain substances such as growth factors and cytokines secreted by feeder cells.

[0096] In addition, "feeder cells" or "feeding" refers to cells that are co-cultured with other types of cells to support the cells and provide an environment in which they can grow. Feeder cells can be derived from the same type of cells as they support, or from different types. For example, in the case of feeder cells for human cells, human skin fibroblasts or human embryonic stem cells can be used, and primary cultures of mouse embryonic fibroblasts and immortalized mouse embryonic fibroblasts can also be used. Feeder cells can be deactivated by irradiation or treatment with mitomycin C, etc.

[0097] In this specification, "adhesion" refers to the attachment of cells to a container, for example, cells adhere to a sterile plastic (or coated plastic) cell culture dish or flask in the presence of a suitable culture medium. There are also cells that cannot be maintained in culture or do not grow without adhering to the cell culture container. In contrast, non-adherent cells can be maintained and proliferated in culture without adhering to the container.

[0098] In this specification, "culture" means maintaining, growing and / or differentiating cells in an in vitro environment. "Cultivating" means maintaining, proliferating (growing) and / or differentiating cells in a tissue or in vitro, for example, in a cell culture dish or flask. Cultivation includes two-dimensional culture (planar culture) and three-dimensional culture (suspension culture).

[0099] In this specification, "enrichment" and "enrichment" refer to increasing the amount of specific constituents in a composition such as a composition of a cell, and "enriched" refers to a cell group whose amount has increased compared to the ratio of a specific constituent in a cell group before enrichment when used to describe a composition of a cell such as a cell group. For example, a composition such as a cell group can be enriched for a target cell type, so that the ratio of the target cell type is increased compared to the ratio of the target cells present in the cell group before enrichment. The cell group can also be enriched for the target cell type by cell selection and screening methods known in the art. The cell group can also be enriched by a specific screening or selection process described in this specification. In a specific embodiment of the present invention, by a method for enriching a target cell group, the cell group is at least enriched by 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% relative to the target cell group.

[0100] In this specification, "deplete" and "depletion" refer to reducing the amount of a specific constituent in a composition such as a cell or a composition of cells; "depleted" when used to describe a cell or a composition of cells such as a cell group refers to a cell group in which the amount of a specific constituent is reduced compared to the proportion of the constituent in the cell group before depletion. For example, a composition such as a cell group can be depleted for a target cell type, so that the proportion of the target cell type is reduced compared to the proportion of target cells present in the cell group before depletion. The cell group can also be depleted for the target cell type by cell selection and screening methods known in the art. The cell group can also be depleted by a specific screening or selection process described in this specification. In a specific embodiment of the present invention, the cell group is reduced (depleted) by at least 50%, 80%, 85%, 90%, 95%, 97%, 98% or 99% relative to the target cell group by a method for depleting the target cell group.

[0101] In this specification, "purify" and "purification" refer to the removal of impurities in a composition such as a cell composition to make a specific constituent pure. "Purified" when used to describe a cell composition such as a cell group refers to a cell group in which the amount of impurities is reduced compared to the proportion of the constituent in the cell group before purification, and the purity of the specific constituent is increased. For example, a composition such as a cell group can be purified for a target cell type, so that the proportion of the target cell type is increased compared to the proportion of target cells present in the cell group before purification. The cell group can also be purified for the target cell type by cell selection and screening methods known in the art. The cell group can also be purified by a specific screening or selection process described in this specification. In a specific embodiment of the present invention, by a method for purifying a target cell group, the purity of the target cell group is at least 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99%, or can reach a level where no impurities (including mixed cells) can be detected.

[0102] In this specification, "factors having CDK8 / 19 inhibitory activity" refers to all substances having CDK8 / 19 inhibitory activity. Compared with other proteins in the same CDK family, CDK8 is not essential for cell proliferation, and under normal circumstances, the effect of CDK8 inhibition on cell proliferation is not obvious. CDK19 and CDK8 are similar, and the inhibition of CDK8 is usually accompanied by the inhibition of CDK19.

[0103] "Growth factors" are endogenous proteins that promote differentiation and / or proliferation of specific cells. "Growth factors" include, for example, epidermal growth factor (EGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), keratinocyte growth factor (KGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), transferrin, various interleukins (e.g., IL-1 to IL-18), various colony stimulating factors (e.g., granulocyte / macrophage colony stimulating factor (GM-CSF)), various interferons (e.g., IFN-γ, etc.), and other cytokines that affect stem cells, such as stem cell factor (SCF) and erythropoietin (Epo).

[0104] In the present specification, "ROCK inhibitor" refers to a substance that inhibits Rho kinase (ROCK: Rho-associated coiled-coil protein kinase), and may be a substance that inhibits either ROCK I or ROCK II. The ROCK inhibitor is not particularly limited as long as it has the above-mentioned function, and examples thereof include N-(4-pyridyl)-4β-[(R)-1-aminoethyl]cyclohexane-1α-carboxamide (sometimes referred to as Y-27632), Fasudil (HA1077), (2S)-2-methyl-1-[(4-methyl-5-isoquinolyl)sulfonyl]hexahydro-1H-1,4-diazepine (H-1152), 4β-[(1R)-1-aminoethyl]-N-(4-pyridyl)benzo-1α-carboxamide (Wf-536), N-(1H-pyrrolo[2,3-b]pyridine -4-yl)-4β(R)-1-aminoethyl]cyclohexane-1α-carboxamide (Y-30141), N-(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]-oxy}benzamide (GSK269962A), N-(6-fluoro-1H-indazol-5-yl)-6-methyl-2-oxo-4-[4-(trifluoromethyl)phenyl]-3,4-dihydro-1H-pyridine-5-carboxamide (GSK429286A). The ROCK inhibitor is not limited to the above, and antisense oligonucleotides against ROCK mRNA, siRNA, antibodies binding to ROCK, dominant negative ROCK mutants, etc. can also be used as ROCK inhibitors, which are commercially available or can be synthesized according to known methods.

[0105] In this specification, "GSK3β inhibitor" refers to a substance that has inhibitory activity on GSK3β (glycogen synthase kinase 3β). GSK3 (glycogen synthase kinase 3) is a type of serine / threonine protein kinase and is involved in many signal pathways related to glycogen production, cell apoptosis, stem cell maintenance, etc. There are two subtypes of GSK3, α and β. The "GSK3β inhibitor" used in the present invention is not particularly limited as long as it has GSK3β inhibitory activity, and may also be a substance having both GSK3β inhibitory activity and GSK3α inhibitory activity.

[0106] Examples of GSK3β inhibitors include CHIR 98014 (2-[[2-[(5-nitro-6-aminopyridin-2-yl)amino]ethyl]amino)-4-(2,4-dichlorophenyl)-5-(1H-imidazol-1-yl)pyrimidine), CHIR 99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-2-pyrimidinyl)-amino]ethyl]amino)nicotine nitrile, and TDZD-8 (4 -benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione, SB216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione), TWS-119 (3-[6-(3-aminophenyl)-7H-pyrrolo[[2,3-d]pyrimidin-4-yl]oxy)phenol, Kenpaullone, 1- Azakenpaullone, SB216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrolo-2,5-dione), SB415286 (3-[(3-chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione) and AR-AO144-18, CT9902 1, CT20026, BIO, BIO-acetone oxime, pyridocarbazole-cyclopentadienylruthenium complex, OTDZT, α-4-dibromoacetophenone, lithium, etc. GSK3β is not limited to the above, and antisense oligonucleotides against GSK3β mRNA, siRNA, antibodies binding to GSK3β, dominant negative GSK3β mutants, etc. can also be used as GSK3β inhibitors, which are commercially available or can be synthesized according to known methods.

[0107] In the present specification, "serum substitutes" include, for example, Knockout serum replacement (KSR: Invitrogen), StemSure serum replacement (Wako), B-27 supplement, N2 supplement, albumin (e.g., lipid-rich albumin), insulin, transferrin, fatty acids, collagen precursors, trace elements (e.g., zinc, selenium (e.g., sodium selenite)), 2-mercaptoethanol, 3'-thiolglycerol or a mixture thereof (e.g., ITS-G). B-27 supplement, KSR, StemSure serum replacement, ITS-G are preferred as serum substitutes. When the serum substitute is added to the culture medium, the concentration in the culture medium is 0.01% to 10% by weight, preferably, 0.1% to 2% by weight. In the present invention, it is preferred to use a "serum substitute" instead of serum.

[0108] In the present specification, "FGFR1 inhibitor" refers to a substance that has inhibitory activity against fibroblast growth factor receptor (FGFR) 1. FGFR1 is a receptor with high affinity for growth factors FGF1 to FGF17, and is a member of the 4-membrane-penetrating tyrosine kinase family (FGFR1, 2, 3, 4). FGFR1 inhibitors are not particularly limited as long as they have FGFR1 inhibitory activity, and may also be substances that have both FGFR1 inhibitory activity and other FGFR inhibitory activity. In the present specification, "FGFR1 inhibitor" refers to a substance that contains a slight FGFR1 inhibitory activity, preferably a substance that inhibits FGFR1 by 50% or more, and more preferably a 50% inhibitory concentration (IC 50) of FGFR1. 50 ) is less than 1 μM, and more preferably less than 100 nM. The determination method of FGFR1 inhibitory activity can be selected from a known method, and for example, the determination method using EnzyChrom Kinase AssayKit (BioAssay Systems Company) can be listed. Conventional known FGFR1 inhibitors can be used, which can be found in patent documents or non-patent documents.

[0109] For example, in the present specification, "FGFR1 inhibitor" refers to a compound (or its salt) having an inhibitory activity against FGFR1 among compounds having the structural formula shown below, in addition to the compounds shown below (compound group D), preferably, among compounds I and II having the structural formula shown below, the 50% inhibitory concentration (IC) of FGFR1 is 50 ) is 1 μM or less, more preferably 100 nM or less.

[0110] (Compound I)

[0111] Compound I includes compounds represented by the following formula 1 or salts thereof:

[0112] [Chemistry 1]

[0113]

[0114] [In the formula, ring AB represents a bicyclic heterocyclic ring having one or more substituents. (Ring AB may also be a tricyclic heterocyclic ring having one or more substituents)].

[0115] Preferably, in the formula, ring AB represents a bicyclic nitrogen-containing heterocyclic ring having three substituents. Examples of the substituents include the substituents shown below or the substituents possessed by compound group D, and preferably represents the substituents possessed by compound group D.

[0116] (Compound II)

[0117] Compound II may include a compound represented by the following formula 2 or a salt thereof:

[0118] [Chemistry 2]

[0119]

[0120] [wherein, ring D represents a 5- to 6-membered monocyclic nitrogen-containing heterocyclic ring which may have a substituent; and represents that at least one nitrogen-containing heterocyclic ring is contained in addition to ring D].

[0121] Preferably, in the formula, ring D represents an aromatic ring containing 1 or 2 nitrogen atoms which may have a substituent.

[0122] Furthermore, preferably, as one or more nitrogen-containing heterocyclic rings other than ring D, piperazine which may have a substituent is exemplified.

[0123] Examples of the substituent include the substituents shown below or the substituents possessed by the compound group D, and preferably, the substituents possessed by the compound group D are shown.

[0124] In the present specification, examples of the “heterocycle” include aromatic heterocycles and non-aromatic heterocycles each containing 1 to 4 heteroatoms selected from nitrogen atoms, sulfur atoms and oxygen atoms as ring-constituting atoms in addition to carbon atoms.

[0125] In the present specification, the “aromatic heterocycle” includes, for example, a 5- to 14-membered (preferably 5- to 10-membered) aromatic heterocycle containing, in addition to carbon atoms, 1 to 4 heteroatoms selected from nitrogen atoms, sulfur atoms and oxygen atoms as ring-constituting atoms. Preferred examples of the “aromatic heterocycle” include: 5- to 6-membered monocyclic aromatic heterocycles such as thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, triazole, tetrazole and triazine;

[0126] benzothiophene, benzofuran, benzimidazole, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzotriazole, imidazopyridine, thienopyridine, furopyridine, pyrrolopyridine, pyrazolopyridine, oxazolopyridine, thiazolopyridine, imidazopyrazine, imidazopyrimidine, thienopyrimidine, furopyrimidine, pyrrolopyrimidine, pyrazolopyrimidine, oxazolopyrimidine , thiazolopyrimidine, pyrazolopyrimidine, pyrazolotriazine, naphtho[2,3-b]thiophene, phenoxathiol, indole, isoindole, 1H-indazole, purine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, carbazole, β-carboline, phenidine, acridine, phenazine, phenothiazine, phenoxazine and the like 8 to 14-membered condensed polycyclic (preferably 2 or 3 rings) aromatic heterocycles.

[0127] In the present specification, examples of the “non-aromatic heterocycle” include 3- to 14-membered (preferably 4- to 10-membered) non-aromatic heterocycles containing 1 to 4 heteroatoms selected from nitrogen atoms, sulfur atoms and oxygen atoms as ring-constituting atoms in addition to carbon atoms. Preferred examples of the “non-aromatic heterocycle” include: 3- to 8-membered monocyclic non-aromatic heterocycles such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, imidazoline, imidazoline, oxazoline, oxazolidine, pyrazoline, pyrazolidine, thiazoline, thiazolidine, tetrahydroisothiazole, tetrahydrooxazole, tetrahydroisoxazole, piperidine, piperazine, tetrahydropyridine, dihydropyridine, dihydrothiopyran, tetrahydropyrimidine, tetrahydropyridazine, dihydropyran, tetrahydropyran, tetrahydrothiopyran, morpholine, thiomorpholine, azepane, diazepane, azepane, azooctane, and diazaoctane;

[0128] 9- to 14-membered condensed polycyclic (preferably 2- or 3-ring) non-aromatic heterocyclic rings such as dihydrobenzofuran, dihydrobenzimidazole, dihydrobenzoxazole, dihydrobenzothiazole, dihydrobenzisothiazole, dihydronaphtho[2,3-b]thiophene, tetrahydroisoquinoline, tetrahydroquinoline, 4H-quinolizine, indoline, isoindoline, tetrahydrothieno[2,3-c]pyridine, tetrahydrobenzazepine, tetrahydroquinoxaline, tetrahydrophenidine, hexahydrophenothiazine, hexahydrophenoxazine, tetrahydrophthalazine, tetrahydronaphthyridine, tetrahydroquinazoline, tetrahydrocinnoline, tetrahydrocarbazole, tetrahydro-β-carboline, tetrahydroacridine, tetrahydrophenazine, tetrahydrothiodibenzopyran, and octahydroisoquinoline.

[0129] In the present specification, the “nitrogen-containing heterocycle” includes “heterocycles” containing at least one nitrogen atom as a ring-constituting atom.

[0130] Hereinafter, the definition of each substituent used in the present specification is described in detail. Unless otherwise specified, each substituent has the following definition.

[0131] In the present specification, examples of the "halogen atom" include fluorine, chlorine, bromine, and iodine.

[0132] In this manual, "C 1-6 Examples of the "alkyl group" include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl and 2-ethylbutyl.

[0133] In this specification, "halogenated C 1-6 "Alkyl" includes, for example, C alkyl groups which may have 1 to 7, preferably 1 to 5, halogen atoms. 1-6Alkyl. Specific examples include methyl, chloromethyl, difluoromethyl, trichloromethyl, trifluoromethyl, ethyl, 2-bromoethyl, 2,2,2-trifluoroethyl, tetrafluoroethyl, pentafluoroethyl, propyl, 2,2-difluoropropyl, 3,3,3-trifluoropropyl, isopropyl, butyl, 4,4,4-trifluorobutyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 5,5,5-trifluoropentyl, hexyl, and 6,6,6-trifluorohexyl.

[0134] In this manual, "C 2-6 Examples of the “alkenyl group” include ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3-hexenyl and 5-hexenyl.

[0135] In this manual, "C 2-6 The term “alkynyl” includes, for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl and 4-methyl-2-pentynyl.

[0136] In this manual, "C 3-10 Examples of the "cycloalkyl group" include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl and adamantyl.

[0137] In this specification, "halogenated C 3-10 The "cycloalkyl" group includes, for example, C-1-1-2-3 halogen atoms. 3-10 Cycloalkyl: Specific examples include cyclopropyl, 2,2-difluorocyclopropyl, 2,3-difluorocyclopropyl, cyclobutyl, difluorocyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0138] In this manual, "C 3-10 Examples of the "cycloalkenyl group" include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.

[0139] In this manual, "C 6-14 Examples of the “aryl group” include phenyl, 1-naphthyl, 2-naphthyl, 1-anthryl, 2-anthryl and 9-anthryl.

[0140] In this manual, "C 7-16 Examples of the "arylalkyl group" include benzyl, phenethyl, naphthylmethyl and phenylpropyl.

[0141] In this manual, "C 1-6 Examples of the "alkoxy group" include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy and hexyloxy.

[0142] In this specification, "halogenated C 1-6 The "alkoxy group" may include, for example, C having 1 to 7, preferably 1 to 5 halogen atoms. 1-6 Alkoxy: Specific examples include methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isobutoxy, sec-butoxy, pentyloxy, and hexyloxy.

[0143] In this manual, "C 3-10 Examples of the "cycloalkyloxy group" include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy and cyclooctyloxy.

[0144] In this manual, "C 1-6 Examples of the "alkylthio group" include methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio, pentylthio and hexylthio.

[0145] In this specification, "halogenated C 1-6 "Alkylthio" can be exemplified by C which may have 1 to 7, preferably 1 to 5 halogen atoms. 1-6 Alkylthio group: Specific examples include methylthio, difluoromethylthio, trifluoromethylthio, ethylthio, propylthio, isopropylthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio, and hexylthio.

[0146] In this manual, "C 1-6 Examples of the "alkyl-carbonyl group" include acetyl, propionyl, butyryl, 2-methylpropionyl, valeryl, 3-methylbutyryl, 2-methylbutyryl, 2,2-dimethylpropionyl, hexanoyl, and heptanoyl.

[0147] In this specification, "halogenated C 1-6 "Alkyl-carbonyl" may include, for example, C having 1 to 7, preferably 1 to 5 halogen atoms. 1-6 Alkyl-carbonyl. Specific examples include acetyl, chloroacetyl, trifluoroacetyl, trichloroacetyl, propionyl, butyryl, valeryl, and hexanoyl.

[0148] In this manual, "C 1-6Examples of the "alkoxy-carbonyl group" include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl and hexyloxycarbonyl.

[0149] In this manual, "C 6-14 Examples of the "aryl-carbonyl group" include benzoyl, 1-naphthoyl and 2-naphthoyl.

[0150] In this manual, "C 7-16 Examples of the "arylalkyl-carbonyl group" include phenylacetyl and phenylpropionyl.

[0151] In the present specification, examples of the “5- to 14-membered aromatic heterocyclic carbonyl group” include nicotinyl, isonicotinyl, thenoyl, and furoyl.

[0152] In the present specification, examples of the "3- to 14-membered non-aromatic heterocyclic carbonyl group" include morpholinylcarbonyl, piperidinylcarbonyl, and pyrrolidinylcarbonyl.

[0153] In this specification, "mono- or di-C 1-6 Examples of the "alkyl-carbamoyl group" include a methylcarbamoyl group, an ethylcarbamoyl group, a dimethylcarbamoyl group, a diethylcarbamoyl group, and an N-ethyl-N-methylcarbamoyl group.

[0154] In this specification, "mono- or di-C 7-16 Examples of the "arylalkyl-carbamoyl group" include benzylcarbamoyl and phenylethylcarbamoyl.

[0155] In this manual, "C 1-6 Examples of the "alkylsulfonyl group" include methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, sec-butylsulfonyl and tert-butylsulfonyl.

[0156] In this specification, "halogenated C 1-6 "Alkylsulfonyl" can be exemplified by C which may have 1 to 7, preferably 1 to 5 halogen atoms. 1-6 Alkylsulfonyl group. Specific examples include methanesulfonyl, difluoromethanesulfonyl, trifluoromethanesulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, 4,4,4-trifluorobutylsulfonyl, pentanesulfonyl, and hexanesulfonyl.

[0157] In this manual, "C 6-14 Examples of the "arylsulfonyl group" include benzenesulfonyl, 1-naphthalenesulfonyl and 2-naphthalenesulfonyl.

[0158] In the present specification, examples of the “substituent” include a halogen atom, a cyano group, a nitro group, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an acyl group, an optionally substituted amino group, an optionally substituted carbamoyl group, an optionally substituted carbamoyl group, an optionally substituted sulfamoyl group, an optionally substituted hydroxyl group, an optionally substituted hydrosulfide (SH) group, and an optionally substituted silyl group.

[0159] In the present specification, the term "hydrocarbon group" (including the term "hydrocarbon group" in "hydrocarbon group which may be substituted") includes, for example: 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-14 Aromatic group, C 7-16 Aromatic alkyl.

[0160] In the present specification, the “hydrocarbon group which may be substituted” includes, for example, hydrocarbon groups which may be substituents selected from the substituent group A described below.

[0161] [Substituent Group A]

[0162] (1) halogen atoms,

[0163] (2) Nitro,

[0164] (3) cyano group,

[0165] (4) oxo group,

[0166] (5) hydroxyl group,

[0167] (6) Halogenated C 1-6 Alkoxy,

[0168] (7)C 6-14 Aryloxy (e.g., phenoxy, naphthoxy),

[0169] (8)C 7-16 Arylalkoxy (eg, benzyloxy),

[0170] (9) a 5- to 14-membered aromatic heterocyclic oxy group (e.g., a pyridyloxy group),

[0171] (10) a 3- to 14-membered non-aromatic heterocyclic oxy group (e.g., morpholinyloxy, piperidinyloxy),

[0172] (11)C 1-6 Alkyl-carbonyloxy (e.g. acetyloxy, propionyloxy),

[0173] (12)C 6-14 Aryl-carbonyloxy (e.g., benzyloxy, 1-naphthyloxy, 2-naphthyloxy),

[0174] (13)C 1-6 Alkoxy-carbonyloxy (e.g., methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy),

[0175] (14) Single or Dual C 1-6 Alkyl-carbamoyloxy (e.g., methylcarbamoyloxy, ethylcarbamoyloxy, dimethylcarbamoyloxy, diethylcarbamoyloxy),

[0176] (15)C 6-14 Aryl-carbamoyloxy (e.g., phenylcarbamoyloxy, naphthylcarbamoyloxy),

[0177] (16) a 5- to 14-membered aromatic heterocyclic carbonyloxy group (e.g., nicotinyloxy group),

[0178] (17) a 3- to 14-membered non-aromatic heterocyclic carbonyloxy group (e.g., morpholinylcarbonyloxy group, piperidinylcarbonyloxy group),

[0179] (18) Halogenated C 1-6 Alkylsulfonyloxy (e.g., methanesulfonyloxy, trifluoromethanesulfonyloxy),

[0180] (19) can be obtained by C 1-6 Alkyl substituted C 6-14 an arylsulfonyloxy group (e.g., benzenesulfonyloxy, toluenesulfonyloxy),

[0181] (20) Halogenated C 1-6 Alkylthio,

[0182] (21) a 5- to 14-membered aromatic heterocyclic group,

[0183] (22) a 3- to 14-membered non-aromatic heterocyclic group,

[0184] (23) Formyl group,

[0185] (24) carboxyl group,

[0186] (25) Halogenated C 1-6 Alkyl-carbonyl,

[0187] (26)C 6-14 Aromatic-carbonyl,

[0188] (27) a 5- to 14-membered aromatic heterocyclic carbonyl group,

[0189] (28) a 3- to 14-membered non-aromatic heterocyclic carbonyl group,

[0190] (29)C 1-6 Alkoxy-carbonyl,

[0191] (30)C6-14 Aryloxy-carbonyl (e.g., phenoxycarbonyl, 1-naphthoxycarbonyl, 2-naphthoxycarbonyl),

[0192] (31)C 7-16 Arylalkoxy-carbonyl (e.g., benzyloxycarbonyl, phenethoxycarbonyl),

[0193] (32) carbamoyl,

[0194] (33)Thiocarbamoyl,

[0195] (34) Single or Dual-C 1-6 Alkyl-carbamyl,

[0196] (35)C 6-14 Aryl-carbamoyl (e.g., phenylcarbamoyl),

[0197] (36) a 5- to 14-membered aromatic heterocyclic carbamoyl group (e.g., pyridylcarbamoyl, thienylcarbamoyl),

[0198] (37) a 3- to 14-membered non-aromatic heterocyclic carbamoyl group (e.g., morpholinylcarbamoyl, piperidinylcarbamoyl),

[0199] (38) Halogenated C 1-6 Alkylsulfonyl,

[0200] (39)C 6-14 Arylsulfonyl,

[0201] (40) a 5- to 14-membered aromatic heterocyclic sulfonyl group (e.g., pyridinesulfonyl, thiophenesulfonyl),

[0202] (41) Halogenated C 1-6 Alkylsulfinyl,

[0203] (42)C 6-14 aromatic sulfinyl (e.g., benzenesulfinyl, 1-naphthylsulfinyl, 2-naphthylsulfinyl),

[0204] (43) a 5- to 14-membered aromatic heterocyclic sulfinyl group (e.g., pyridylsulfinyl, thienylsulfinyl),

[0205] (44) amino group,

[0206] (45) Single or Double C 1-6 Alkylamino (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, diethylamino, dipropylamino, dibutylamino, N-ethyl-N-methylamino),

[0207] (46) Single or Double C 6-14an aromatic amino group (eg, phenylamino),

[0208] (47) a 5- to 14-membered aromatic heterocyclic amino group (e.g., aminopyridine),

[0209] (48)C 7-16 Arylalkylamino (e.g., benzylamino),

[0210] (49) carboxamido group,

[0211] (50)C 1-6 Alkyl-carbonylamino (e.g., acetylamino, propionylamino, butyrylamino),

[0212] (51)(C 1-6 Alkyl)(C 1-6 alkyl-carbonyl)amino (e.g., N-acetyl-N-methylamino),

[0213] (52)C 6-14 Aryl-carbonylamino (e.g., phenylcarbonylamino, naphthylcarbonylamino),

[0214] (53)C 1-6 Alkoxy-carbonylamino (e.g., methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, butoxycarbonylamino, tert-butoxycarbonylamino),

[0215] (54)C 7-16 Arylalkoxy-carbonylamino (e.g. benzyloxycarbonylamino),

[0216] (55)C 1-6 Alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino),

[0217] (56) can be obtained by C 1-6 Alkyl substituted C 6-14 Arylsulfonylamino (e.g., benzenesulfonylamino, toluenesulfonylamino),

[0218] (57) Halogenated C 1-6 alkyl,

[0219] (58)C 2-6 Alkenyl,

[0220] (59)C 2-6 Alkynyl,

[0221] (60)C 3-10 Cycloalkyl,

[0222] (61)C 3-10 Cycloalkenyl, and

[0223] (62)C 6-14 Aromatic group.

[0224] The number of the substituents in the "optionally substituted hydrocarbon group" is, for example, 1 to 5, preferably 1 to 3. When the number of substituents is 2 or more, each substituent may be the same or different.

[0225] In the present specification, the “heterocyclic group” (including the “heterocyclic group” in the “heterocyclic group which may be substituted”) includes, for example: (i) aromatic heterocyclic groups, (ii) non-aromatic heterocyclic groups, and (iii) 7- to 10-membered composite crosslinked ring groups, each of which contains 1 to 4 heteroatoms selected from nitrogen atoms, sulfur atoms and oxygen atoms as ring-constituting atoms in addition to carbon atoms.

[0226] In the present specification, the “aromatic heterocyclic group” (including “5- to 14-membered aromatic heterocyclic group”) can be exemplified by a 5- to 14-membered (preferably 5- to 10-membered) aromatic heterocyclic group containing, in addition to carbon atoms, 1 to 4 heteroatoms selected from nitrogen atoms, sulfur atoms and oxygen atoms as ring-constituting atoms.

[0227] Preferred examples of the "aromatic heterocyclic group" include: 5- to 6-membered monocyclic aromatic heterocyclic groups such as thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, triazolyl, tetrazolyl, and triazinyl;

[0228] benzothienyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, imidazopyridyl, thienopyridyl, furopyridyl, pyrrolopyridyl, pyrazolopyridyl, oxazolopyridyl, thiazolopyridyl, imidazopyrazinyl, imidazopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, oxazolopyridinyl, thiazolopyridinyl, imidazopyrazinyl, imidazopyrimidinyl, thienopyrimidinyl, furopyrimidinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, oxazolopyrimidinyl 8-14 membered condensed polycyclic (preferably 2 or 3 ring) aromatic heterocyclic groups such as pyrimidinyl, thiazolopyrimidinyl, pyrazolotriazinyl, naphtho[2,3-b]thienyl, phenoxathiyl, indolyl, isoindolyl, 1H-indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, β-carbolinyl, phenidinyl, acridinyl, phenazinyl, phenothiazinyl and phenoxazinyl.

[0229] In the present specification, “non-aromatic heterocyclic group” (including “3- to 14-membered non-aromatic heterocyclic group”) can be exemplified by: a 3- to 14-membered (preferably 4- to 10-membered) non-aromatic heterocyclic group containing, in addition to carbon atoms, 1 to 4 heteroatoms selected from nitrogen atoms, sulfur atoms and oxygen atoms as ring-constituting atoms.

[0230] Preferred examples of the "non-aromatic heterocyclic group" include aziridine, oxirane, thiirane, azetidinyl, oxetanyl, thietanyl, tetrahydrothiophenyl, tetrahydrofuran, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, oxazolinyl, oxazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolinyl, thiazolidinyl, tetrahydroisothiazolyl, tetrahydrooxazolyl , tetrahydroisoxazolyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydropyridinyl, dihydrothiopyranyl, tetrahydropyrimidinyl, tetrahydropyridazinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, thiomorpholinyl, azepanyl, diazepanyl, azepanenyl, oxepinyl, azooctanyl, diazaoctanyl and the like 3-8 membered monocyclic non-aromatic heterocyclic groups;

[0231] a 9- to 14-membered condensed polycyclic (preferably 2- or 3-ring) non-aromatic heterocyclic group such as a dihydrobenzofuranyl group, a dihydrobenzimidazolyl group, a dihydrobenzoxazolyl group, a dihydrobenzothiazolyl group, a dihydrobenzisothiazolyl group, a dihydronaphtho[2,3-b]thienyl group, a tetrahydroisoquinolyl group, a tetrahydroquinolyl group, a 4H-quinolizinyl group, an indolyl group, an isoindolyl group, a tetrahydrothieno[2,3-c]pyridinyl group, a tetrahydrobenzazepinyl group, a tetrahydroquinoxalinyl group, a tetrahydrophenidinyl group, a hexahydrophenothiazinyl group, a hexahydrophenoxazinyl group, a tetrahydrophthalazinyl group, a tetrahydronaphthyridinyl group, a tetrahydroquinazolinyl group, a tetrahydrocinnolinyl group, a tetrahydrocarbazolyl group, a tetrahydro-β-carbolinyl group, a tetrahydroacridinyl group, a tetrahydrophenazinyl group, a tetrahydrothiodibenzopyranyl group, and an octahydroisoquinolyl group.

[0232] In the present specification, preferred examples of the "7- to 10-membered composite cross-linked ring group" include a quinuclidine ring group and a 7-azabicyclo[2.2.1]heptyl group.

[0233] In the present specification, the “nitrogen-containing heterocyclic group” includes a “heterocyclic group” containing at least one nitrogen atom as a ring-constituting atom.

[0234] In the present specification, examples of the “optionally substituted heterocyclic group” include a heterocyclic group which may have a substituent selected from the above-mentioned substituent group A.

[0235] The number of substituents in the "optionally substituted heterocyclic group" is, for example, 1 to 3. When the number of substituents is 2 or more, each substituent may be the same or different.

[0236] In the present specification, the term "acyl group" includes, for example, "acyl group" which may each have "a halogen atom, a halogenated C 1-6 Alkoxy, hydroxy, nitro, cyano, amino and carbamoyl 1 to 3 substituents C 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkenyl, C 6-14Aromatic group, C 7-16 arylalkyl, 5- to 14-membered aromatic heterocyclic group and 1 or 2 substituents of 3- to 14-membered non-aromatic heterocyclic group”, formyl, carboxyl, carbamoyl, carbamothioyl, sulfinic acid, sulfonic acid, sulfamoyl and phosphonyl.

[0237] In addition, examples of the "acyl group" include a hydrocarbon-sulfonyl group, a heterocyclic-sulfonyl group, a hydrocarbon-sulfinyl group, and a heterocyclic-sulfinyl group.

[0238] Here, hydrocarbon-sulfonyl group refers to a sulfonyl group bonded to a hydrocarbon group, heterocyclic-sulfonyl group refers to a sulfonyl group bonded to a heterocyclic group, hydrocarbon-sulfinyl group refers to a sulfinyl group bonded to a hydrocarbon group, and heterocyclic-sulfinyl group refers to a sulfinyl group bonded to a heterocyclic group.

[0239] Preferred examples of "acyl" include formyl, carboxyl, C 1-6 Alkyl-carbonyl, C 2-6 Alkenyl-carbonyl (e.g., crotonyl), C 3-10 Cycloalkyl-carbonyl (e.g., cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, cycloheptanecarbonyl), C 3-10 Cycloalkenyl-carbonyl (e.g., 2-cyclohexenecarbonyl), C 6-14 Aromatic-carbonyl, C 7-16 Arylalkyl-carbonyl, 5- to 14-membered aromatic heterocyclic carbonyl, 3- to 14-membered non-aromatic heterocyclic carbonyl, C 1-6 Alkoxy-carbonyl, C 6-14 Aryloxy-carbonyl (e.g., phenoxycarbonyl, naphthoxycarbonyl), C 7-16 Arylalkyloxy-carbonyl (e.g., benzyloxycarbonyl, phenethoxycarbonyl), carbamoyl, mono- or di-C 1-6 Alkyl-carbamoyl, mono- or di-C 2-6 Alkenyl-carbamoyl (e.g., diallylcarbamoyl), mono- or di-C 3-10 Cycloalkyl-carbamoyl (e.g., cyclopropylcarbamoyl), mono- or di-C 6-14 Aryl-carbamoyl (e.g., phenylcarbamoyl), mono- or di-C 7-16 Arylalkyl-carbamoyl, 5- to 14-membered aromatic heterocyclic carbamoyl (e.g., pyridylcarbamoyl), carbamothioyl, mono- or di-C 1-6 Alkyl-carbamoyl (e.g., methylcarbamoyl, N-ethyl-N-methylcarbamoyl), mono- or di-C 2-6 Alkenyl-carbamoyl (e.g., diallylcarbamoyl), mono- or di-C 3-10 Cycloalkyl-carbamoyl (e.g., cyclopropylcarbamoyl, cyclohexylcarbamoyl), mono- or di-C 6-14Aryl-thiocarbamoyl (e.g., phenylthiocarbamoyl), mono- or di-C 7-16 Arylalkyl-thiocarbamoyl (e.g., benzylthiocarbamoyl, phenylethylthiocarbamoyl), 5- to 14-membered aromatic heterocyclic thiocarbamoyl (e.g., pyridylthiocarbamoyl), sulfinic acid, C 1-6 Alkylsulfinyl (e.g., methylsulfinyl, ethylsulfinyl), sulfonic acid, C 1-6 Alkylsulfonyl, C 6-14 Aromatic sulfonyl, phosphonyl, mono- or di-C 1-6 Alkylphosphonyl (eg, dimethylphosphonyl, diethylphosphonyl, diisopropylphosphonyl, dibutylphosphonyl).

[0240] In the present specification, the term "amino group which may be substituted" includes, for example, a C group which may have "a C group which may each have 1 to 3 substituents selected from the substituent group A" 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 6-14 Aromatic group, C 7-16 Aryl alkyl, C 1-6 Alkyl-carbonyl, C 6-14 Aromatic-carbonyl, C 7-16 Arylalkyl-carbonyl, 5- to 14-membered aromatic heterocyclic carbonyl, 3- to 14-membered non-aromatic heterocyclic carbonyl, C 1-6 Alkoxy-carbonyl, 5- to 14-membered aromatic heterocyclic group, carbamoyl, mono- or di-C 1-6 Alkyl-carbamoyl, mono- or di-C 7-16 Arylalkyl-carbamoyl, C 1-6 Alkylsulfonyl and C 6-14 1 or 2 substituents of an aromatic sulfonyl group" amino group.

[0241] Preferred examples of the amino group which may be substituted include amino, mono- or di-(which may be halogenated C 1-6 alkyl)amino (e.g., methylamino, trifluoromethylamino, dimethylamino, ethylamino, diethylamino, propylamino, dibutylamino), mono- or di-C 2-6 Alkenylamino (e.g., diallylamino), mono- or di-C 3-10 ) cycloalkylamino (e.g., cyclopropylamino, cyclohexylamino), mono- or di-C 6-14 Aromatic amino (e.g., phenylamino), mono- or di-C 7-16 Arylalkylamino (e.g., benzylamino, dibenzylamino), mono- or di- (which may be halogenated C 1-6 Alkyl)-carbonylamino (e.g., acetylamino, propionylamino), mono- or di-C 6-14 Aryl-carbonylamino (e.g., aminobenzoyl), mono- or di-C7-16 Arylalkyl-carbonylamino (e.g., benzylcarbonylamino), mono- or di-5- to 14-membered aromatic heterocyclic carbonylamino (e.g., nicotinylamino, isonicotinylamino), mono- or di-3- to 14-membered non-aromatic heterocyclic carbonylamino (e.g., piperidinecarbonylamino), mono- or di-C 1-6 Alkoxy-carbonylamino (e.g., tert-butyloxycarbonylamino), 5- to 14-membered aromatic heterocyclic amino (e.g., aminopyridine), carbamoylamino, (mono- or di-C 1-6 Alkyl-carbamoyl)amino (e.g., methylcarbamoylamino), (mono- or di-C 7-16 Arylalkyl-carbamoyl)amino (e.g., benzylcarbamoylamino), C 1-6 Alkylsulfonylamino (e.g., methylsulfonylamino, ethylsulfonylamino), C 6-14 Arylsulfonylamino (e.g., benzenesulfonylamino), (C 1-6 Alkyl)(C 1-6 alkyl-carbonyl)amino (e.g., N-acetyl-N-methylamino), (C 1-6 Alkyl)(C 6-14 aryl-carbonyl)amino (e.g., N-benzoyl-N-methylamino).

[0242] In the present specification, the “optionally substituted carbamoyl group” includes, for example, a C group which may have “a C group which may each have 1 to 3 substituents selected from the substituent group A”. 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 6-14 Aromatic group, C 7-16 Aryl alkyl, C 1-6 Alkyl-carbonyl, C 6-14 Aromatic-carbonyl, C 7-16 Arylalkyl-carbonyl, 5- to 14-membered aromatic heterocyclic carbonyl, 3- to 14-membered non-aromatic heterocyclic carbonyl, C 1-6 Alkoxy-carbonyl, 5- to 14-membered aromatic heterocyclic group, carbamoyl, mono- or di-C 1-6 Alkyl-carbamoyl and mono- or di-C 7-16 "aralkyl-carbamoyl" or "aralkyl-carbamoyl" carbamoyl.

[0243] Preferred examples of the substituted carbamoyl group include carbamoyl, mono- or di-C 1-6 Alkyl-carbamoyl, mono- or di-C 2-6 Alkenyl-carbamoyl (e.g., diallylcarbamoyl), mono- or di-C 3-10 Cycloalkyl-carbamoyl (e.g., cyclopropylcarbamoyl, cyclohexylcarbamoyl), mono- or di-C 6-14Aryl-carbamoyl (e.g., phenylcarbamoyl), mono- or di-C 7-16 Arylalkyl-carbamoyl, mono- or di-C 1-6 Alkyl-carbonyl-carbamoyl (e.g., acetylcarbamoyl, propionylcarbamoyl), mono- or di-C 6-14 Aryl-carbonyl-carbamoyl (eg, benzylacylcarbamoyl), 5- to 14-membered aromatic heterocyclic carbamoyl (eg, pyridylcarbamoyl).

[0244] In the present specification, the “optionally substituted carbamoyl group” includes, for example, a C group which may have “a C group which may each have 1 to 3 substituents selected from the substituent group A”. 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 6-14 Aromatic group, C 7-16 Aryl alkyl, C 1-6 Alkyl-carbonyl, C 6-14 Aromatic-carbonyl, C 7-16 Arylalkyl-carbonyl, 5- to 14-membered aromatic heterocyclic carbonyl, 3- to 14-membered non-aromatic heterocyclic carbonyl, C 1-6 Alkoxy-carbonyl, 5- to 14-membered aromatic heterocyclic group, carbamoyl, mono- or di-C 1-6 Alkyl-carbamoyl and mono- or di-C 7-16 "aralkyl-carbamoyl" or "aralkyl-carbamoyl" or "aralkyl-carbamoyl";

[0245] Preferred examples of the substituted carbamoyl group include carbamoyl, mono- or di-C 1-6 Alkyl-carbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, N-ethyl-N-methylcarbamoyl), mono- or di-C 2-6 Alkenyl-carbamoyl (e.g., diallylcarbamoyl), mono- or di-C 3-10 Cycloalkyl-carbamoyl (e.g., cyclopropylcarbamoyl, cyclohexylcarbamoyl), mono- or di-C 6-14 Aryl-carbamoyl (e.g., phenylcarbamoyl), mono- or di-C 7-16 Arylalkyl-thiocarbamoyl (e.g., benzylthiocarbamoyl, phenylethylthiocarbamoyl), mono- or di-C 1-6 Alkyl-carbonyl-carbamoyl (e.g., acetylcarbamoyl, propionylcarbamoyl), mono- or di-C 6-14 Aryl-carbonyl-carbamoyl (eg, benzoylcarbamoyl), 5- to 14-membered aromatic heterocyclic carbamoyl (eg, pyridylcarbamoyl).

[0246] In the present specification, the “sulfamoyl group which may be substituted” includes, for example, a C group which may have “a C group which may each have 1 to 3 substituents selected from the substituent group A”. 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 6-14 Aromatic group, C 7-16 Aryl alkyl, C 1-6 Alkyl-carbonyl, C 6-14 Aromatic-carbonyl, C 7-16 Arylalkyl-carbonyl, 5- to 14-membered aromatic heterocyclic carbonyl, 3- to 14-membered non-aromatic heterocyclic carbonyl, C 1-6 Alkoxy-carbonyl, 5- to 14-membered aromatic heterocyclic group, carbamoyl, mono- or di-C 1-6 Alkyl-carbamoyl and mono- or di-C 7-16 arylalkyl-carbamoyl" sulfamoyl group having 1 or 2 substituents.

[0247] Preferred examples of the sulfamoyl group which may be substituted include sulfamoyl, mono- or di-C 1-6 Alkyl-sulfamoyl (e.g., methylsulfamoyl, ethylsulfamoyl, dimethylsulfamoyl, diethylsulfamoyl, N-ethyl-N-methylsulfamoyl), mono- or di-C 2-6 Alkenyl-sulfamoyl (e.g., diallylsulfamoyl), mono- or di-C 3-10 Cycloalkyl-sulfamoyl (e.g., cyclopropylsulfamoyl, cyclohexylsulfamoyl), mono- or di-C 6-14 Aryl-sulfamoyl (e.g., phenylsulfamoyl), mono- or di-C 7-16 Arylalkyl-sulfamoyl (e.g., benzylsulfamoyl, phenylethylsulfamoyl), mono- or di-C 1-6 Alkyl-carbonyl-sulfamoyl (e.g., acetylsulfamoyl, propionylsulfamoyl), mono- or di-C 6-14 Aryl-carbonyl-sulfamoyl (eg, benzoylsulfamoyl), 5- to 14-membered aromatic heterocyclic sulfamoyl (eg, pyridylsulfamoyl).

[0248] In the present specification, the term "hydroxyl group which may be substituted" includes, for example, C which may have "a C selected from each of which may have 1 to 3 substituents selected from the substituent group A" 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 6-14 Aromatic group, C 7-16 Aryl alkyl, C 1-6 Alkyl-carbonyl, C 6-14 Aromatic-carbonyl, C 7-16Arylalkyl-carbonyl, 5- to 14-membered aromatic heterocyclic carbonyl, 3- to 14-membered non-aromatic heterocyclic carbonyl, C 1-6 Alkoxy-carbonyl, 5- to 14-membered aromatic heterocyclic group, carbamoyl, mono- or di-C 1-6 Alkyl-carbamoyl, mono- or di-C 7-16 Arylalkyl-carbamoyl, C 1-6 Alkylsulfonyl and C 6-14 The hydroxyl group of the "substituent of the aromatic sulfonyl group"

[0249] Preferred examples of the hydroxyl group which may be substituted include: hydroxyl group, C 1-6 Alkoxy, C 2-6 alkenyloxy (e.g., allyloxy, 2-butenyloxy, 2-pentenyloxy, 3-hexenyloxy), C 3-10 Cycloalkyloxy (e.g., cyclohexyloxy), C 6-14 Aryloxy (e.g., phenoxy, naphthoxy), C 7-16 Arylalkyloxy (e.g., benzyloxy, phenethoxy), C 1-6 Alkyl-carbonyloxy (e.g., acetyloxy, propionyloxy, butyryloxy, isobutyryloxy, pivaloyloxy), C 6-14 Aryl-carbonyloxy (e.g., benzoyloxy), C 7-16 Arylalkyl-carbonyloxy (e.g., benzyloxycarbonyl), 5- to 14-membered aromatic heterocyclic carbonyloxy (e.g., nicotinylamino), 3- to 14-membered non-aromatic heterocyclic carbonyloxy (e.g., piperidinylcarbonyloxy), C 1-6 Alkoxy-carbonyloxy (e.g., tert-butoxycarbonyloxy), 5- to 14-membered aromatic heterocyclic oxy (e.g., pyridyloxy), carbamoyloxy, C 1-6 Alkyl-carbamoyloxy (eg, methylcarbamoyloxy), C 7-16 Arylalkyl-carbamoyloxy (e.g., benzylcarbamoyloxy), C 1-6 Alkylsulfonyloxy (e.g., methanesulfonyloxy, ethanesulfonyloxy), C 6-14 Arylsulfonyloxy (eg, benzenesulfonyloxy).

[0250] In the present specification, the term "sulfhydryl group which may be substituted" includes, for example, C which may have "a substituent selected from C which may each have 1 to 3 substituents selected from the substituent group A" 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 6-14 Aromatic group, C 7-16 Aryl alkyl, C 1-6 Alkyl-carbonyl, C 6-14a sulfhydryl group, a halogenated sulfhydryl group, a substituent of an aromatic-carbonyl group and a 5- to 14-membered aromatic heterocyclic group.

[0251] Preferred examples of the substituted sulfhydryl group include sulfhydryl (-SH) group, C 1-6 Alkylthio, C 2-6 alkenylthio (e.g., allylthio, 2-butenylthio, 2-pentenylthio, 3-hexenylthio), C 3-10 Cycloalkylthio (e.g., alkylhexylthio), C 6-14 Arylthio (e.g., phenylthio, naphthylthio), C 7-16 Arylalkylthio (e.g., benzylthio, phenethylthio), C 1-6 Alkyl-carbonylthio (e.g., acetylthio, propionylthio, butyrylthio, isobutyrylthio, pivaloylthio), C 6-14 Aryl-carbonylthio (eg, benzoylthio), 5- to 14-membered aromatic heterocyclic thio (eg, pyridylthio), halogenated thio (eg, pentafluorothio).

[0252] In the present specification, the term "substituted silyl group" includes, for example, a C silyl group having "a C silyl group each having 1 to 3 substituents selected from the substituent group A" 1-6 Alkyl, C 2-6 Alkenyl, C 3-10 Cycloalkyl, C 6-14 Aromatic group and C 7-16 A silane group having 1 to 3 substituents on an aromatic alkyl group.

[0253] Preferred examples of the substituted silyl group include: tri-C 1-6 Alkylsilyl group (eg, trimethylsilyl group, tert-butyl(dimethyl)silyl group).

[0254] More specifically, in the present invention, the FGFR1 inhibitors that can be used include: PD-166866 (1-[2-amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)-pyrimidin-7-yl]-3-tert-butylurea: CAS No.: 192705-79-6), E-3810 (CAS No.: 1058137-23-7), PD-173074 (CAS No.: 219580-11-7), FGFR4-IN-1 (CAS No.: 1708971-72-5), FGFR-IN-1 (CAS No.: 1448169-71-8), FIIN-2 (CAS No.: 1633044-56-0), AZD4547 (CAS No.: 1035270-39-3), FIIN-3 (CAS No.:1637735-84-2), NVP-BGJ398 (CAS No.:1310746-10-1), NVP-BGJ398 (CAS No.:872511-34-7), CH5183284 (CAS No.:1265229-25-1), Derazantinib (CAS No.:1234356-69-4), Derazantinib Racemate, Ferulic acid (CAS No.:1135-24-6), SSR128129E (CAS No.:848318-25-2), SSR128129Efree acid (CAS No.:848463-13-8), Erdafitinib (CAS No.:1346242-81-6), BLU9931 (CAS No.:1538604-68-0), PRN1371 (CAS No.:1802929-43-6), S49076 (CAS No.:1265965-22-7), LY2874455 (CAS No.:1254473-64-7), Linsitinib (CAS No.:867160-71-2), Dovitinib (CAS No.:405169-16-6), Anlotinib (CAS No.:1058156-90-3), Brivanib (CAS No.:649735-46-6), Derazantinib (CAS No.:1234356-69-4), Anlotinib Dihydrochloride (CAS No.:1360460-82-7), ACTB-1003 (CAS No.:939805-30-8), BLU-554 (CAS No.:1707289-21-1)、Rogaratinib(CAS No.:1443530-05-9)、BIBF 1120esylate(CAS No.:656247-18-6)、TG100572Hydrochloride(CAS No.:867331-64-4)、ENMD-2076(CAS No.:934353-76-1)、Brivanib alaninate(CAS No.:649735-63-7)、TG 100572(CAS No.:867334-05-2)、BIBF1120(CAS No.:656247-17-5)、ENMD-2076Tartrate(CAS No.:1291074-87-7)、TSU-68(CASNo.:252916-29-3)、Ponatinib(CAS No.:943319-70-8)、Sulfatinib(CAS No.:1308672-74-3)、LY2784544(CAS No.:1229236-86-5)、Dovitinib lactate(CAS No.:692737-80-7)、SU 5402(CAS No.:215543-92-3)、FGF-401(CAS No.:1708971-55-4)、Tyrosine kinase-IN-1(CAS No.:705946-27-6)、PP58(CAS No.:212391-58-7)、TG 100801Hydrochloride(CAS No.:1018069-81-2)、Crenolanib(CAS No.:670220-88-9)、TG 100801(CAS No.:867331-82-6)、Pazopanib Hydrochloride(CAS No.:635702-64-6)、Pazopanib(CAS No.:444731-52-6)、PD168393(CAS No.:194423-15-9)、Apatinib(CAS No.:1218779-75-9)、Palbociclib isethionate(CAS No.:827022-33-3)、Foretinib(CAS No.:849217-64-7)、Lenvatinib(CAS No.:417716-92-8)、Tandutinib(CAS No.:387867-13-2), etc. or their salts (these compounds are referred to as compound group D). In addition, these compounds, while having FGFR1 inhibitory activity, are preferably at a 50% inhibitory concentration (IC. 50 ) is 100 nM or less, it may have one or more substituents selected from the above.

[0255] In addition, these compounds preferably have FGFR1 inhibitory activity at a 50% inhibitory concentration (IC 50 ) is 100 nM or less, some partial structures (substituents, rings, etc.) may also be converted.

[0256] Preferably, in the present invention, the FGFR1 inhibitor is CAS192705-79-6 (l-[2-amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl]-3-tert-butylurea: CAS No.: 192705-79-6), E-3810 (CAS No.: 1058137-23-7), or PD173074 (CAS No.: 219580-11-7).

[0257] FGFR1 inhibitors are not limited to the compounds shown above. Antisense oligonucleotides against FGFR1 mRNA, siRNA, antibodies binding to FGFR1, dominant negative FGFR1 mutants, etc. can also be used as FGFR1 inhibitors, which are commercially available or can be synthesized according to known methods.

[0258] In this specification, "marker" refers to a cell antigen or its gene that is specifically expressed by a specified cell type, such as a "marker protein" or a "marker gene". Preferably, the marker is a cell surface marker, in which case, concentration, separation and / or detection of surviving cells can be implemented. The marker can be a positive selection marker or a negative selection marker.

[0259] The detection of the marker protein can be performed using an immunoassay using a specific antibody against the marker protein, such as ELISA, immunostaining, flow cytometry, etc. The detection of the marker gene can be performed using nucleic acid amplification methods and / or nucleic acid detection methods known in the art, such as RT-PCR, microarrays, biochips, etc. In this specification, "positive" for a marker protein means positive detection by flow cytometry, and "negative" means detection below the detection limit by flow cytometry. In addition, "positive" for a marker gene means detection by RT-PCR, and "negative" means detection below the detection limit by RT-PCR.

[0260] In the present specification, "expression" is defined as the transcription and / or translation of a specific nucleotide sequence driven by a promoter in a cell.

[0261] In this specification, "cell" refers to a composition of cells, i.e., a cell population, unless otherwise specified. Therefore, "cell" is not only a specific cell or cell population, but also may include one or more other cells or cell populations. A specific cell in "cell" can be improved by enrichment or purification, or by depletion of one or more other cells.

[0262] In this specification, "pluripotency" refers to the ability to differentiate into tissues and cells with various morphologies or functions, and to differentiate into cells of any layer of the three germ layers. "Pluripotency" cannot differentiate into a blastoderm, and therefore does not have the ability to form an individual. In this respect, "pluripotency" is different from "totipotency" which can differentiate into any tissue of an organism including a blastoderm.

[0263] In this specification, "multipotency" refers to the ability to differentiate into multiple cells of a limited number of layers. For example, mesenchymal stem cells, hematopoietic stem cells, and neural stem cells are multipotent but not pluripotent.

[0264] In this specification, "pluripotent stem cells" refer to embryonic stem cells (ES cells) and the same differentiation pluripotency, that is, cells that potentially have the ability to differentiate into various tissues of a living body (entoderm, mesoderm, ectoderm). As cells with the same differentiation pluripotency as ES cells, "artificial pluripotent stem cells" (sometimes referred to as "iPS cells" in this specification) can be cited. Preferably, in the present invention, pluripotent stem cells are human pluripotent stem cells.

[0265] If mouse ES cells are used as "ES cells", various mouse ES cell lines established by inGenious, RIKEN, etc. can be used; if human ES cells are used as "ES cells", various human ES cell lines established by NIH, RIKEN, Kyoto University, Cellartis can be used. For example, CHB-1-CHB-12 strains, RUES1 strains, RUES2 strains, HUES1-HUES28 strains, etc. of NIH, H1 strains, H9 strains of WisCell Research; KhES-1 strains, KhES-2 strains, KhES-3 strains, KhES-4 strains, KhES-5 strains, SSES1 strains, SSES2 strains, SSES3 strains, etc. of RIKEN can be used as ES cell lines.

[0266] “Artificial pluripotent stem cells” refer to cells obtained by introducing specific factors (nuclear reprogramming factors) into mammalian somatic cells or undifferentiated stem cells to reprogram them. Currently, there are various types of "artificial pluripotent stem cells", and iPS cells established by Yamanaka et al. by introducing four factors Oct3 / 4Sox2 ​​Klf4c-Myc into mouse fibroblasts (Takahashi K, Yamanaka S., Cell, (2006) 126: 663-676); iPS cells derived from human cells established by introducing the same four factors into human fibroblasts (Takahashi K, Yamanaka S. et al. Cell, (2007) 131: 861-872.); Nanog-iPS cells established by sorting using Nanog expression as an index after the introduction of the above four factors (Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Nature 448, 313-317.); iPS cells prepared by a method that does not include c-Myc (Nakagawa M, Yamanaka S., et al., Nature Biotechnology, (2008) 26, 101-106); and iPS cells established by non-viral introduction of six factors (Okita K. et al., Nat. Methods, 2011, May, 8 (5): 409-12, Okita K. et al., Stem Cells. 31 (3): 458-66.). In addition, artificial pluripotent stem cells established by introducing four factors, OCT3 / 4, SOX2, NANOG, and LIN28, prepared by Thomson et al. (Yu J., Thomson JA. et al., Science (2007) 318: 1917-1920.), artificial pluripotent stem cells prepared by Daley et al. (Park IH, Daley GQ. et al., Nature (2007) 451: 141-146), artificial pluripotent stem cells prepared by Sakurada et al. (Japanese Patent Laid-Open No. 2008-307007), etc. can also be used.

[0267] In addition, all published papers (e.g., Shi Y., Ding S. et al., Cell Stem Cell, (2008) Vol. 3, No. 5, 568-574; Kim JB., Scholer HR. et al., Nature, (2008) 454, 646-650; Huangfu D., Melton, DA. et al., Nature Biotechnology, (2008) 26, No. 7, 795-797) or patents (e.g., Japanese Patent Laid-Open No. 2008-307007, Japanese Patent Laid-Open No. 2008-283972, US 2008 / 2336610, US 2009 / 047263, WO 2007 / 069666, WO 2008 / 118220, WO 2008 / 124133, WO Any artificial pluripotent stem cell known in the art, such as those described in WO 2008 / 151058, WO 2009 / 006930, WO 2009 / 006997, WO 2009 / 007852).

[0268] As artificial pluripotent cell lines, various iPS cell lines established by NIH, RIKEN (RIKEN), Kyoto University, etc. can be used. For example, in the case of human iPS cell lines, for example, HiPS-RIKEN-1A strain, HiPS-RIKEN-2A strain, HiPS-RIKEN-12A strain, Nips-B2 strain of RIKEN, Ff-WJ-18 strain, Ff-I01s01 strain, Ff-I01s02 strain, Ff-I01s04 strain, Ff-I01s06 strain, Ff-I14s07 strain of Kyoto University can be listed. 03 strain, Ff-I14s04 strain, QHJI01s01 strain, QHJI01s04 strain, QHJI14s03 strain, QHJI14s04 strain, RWMH15s02 strain, F f-MH15s02 strain, 253G1 strain, 201B7 strain, 409B2 strain, 454E2 strain, 606A1 strain, 610B1 strain, 648A1 strain, CDI’s MyCell iPS Cells (21525.102.10A) strain, MyCell iPS Cells (21526.101.10A) strain, etc.

[0269] In the present specification, "embryonic endoderm cells" refer to cells characterized by the expression of at least one marker among SOX17, FOXA2, BMP2, CER and CXCR4.

[0270] In the present specification, "gastrointestinal cells" refer to cells characterized by the expression of at least one marker of HNF1B and HNF4A.

[0271] In the present specification, “posterior foregut cells” refer to cells characterized by the expression of at least one marker among PDX-1, HNF6, and HLXB9.

[0272] In the present specification, "pancreatic precursor cells" refer to cells characterized by the expression of at least one marker among PDX-1, NKX6.1, PTF-1α, GATA4 and SOX9.

[0273] In this specification, "endocrine precursor cells" refer to cells characterized by the expression of at least one marker among chromogranin A, NeuroD and Ngn-3, and the absence of markers of the pancreas-related hormone system (e.g., insulin, etc.). Endocrine precursor cells can also be characterized by the expression of markers such as Pax-4, NKX2-2, Islet-1, PDX-1, PTF-1α, etc.

[0274] Production of cells at various stages of differentiation can be performed by the techniques described in detail below.

[0275] 2. Insulin-producing cells

[0276] The "insulin-producing cells" of the present invention refer to cells characterized by the expression of insulin obtained by differentiating induced pluripotent stem cells in vitro. In more detail, the "insulin-producing cells" of the present invention are characterized by cells expressing both insulin and NKX6.1 markers at a ratio of about 30% or more (i.e., insulin-positive and NKX6.1-positive cells), and cells expressing only insulin as a marker among insulin and NKX6.1 at a ratio of about more than 15% (i.e., insulin-positive and NKX6.1-negative cells, hereinafter described as "Ins+NKX- cells"). In addition, in this specification, "insulin-positive" is sometimes described as "Ins+", NKX6.1-positive is described as "NKX+", and NKX6.1-negative is described as "NKX-". In addition, "insulin-positive and NKX6.1-positive cells" are sometimes described as "Ins+NKX+ cells", and insulin-positive and NKX6.1-negative cells are "described as Ins+NKX- cells".

[0277] The upper limit of the ratio of Ins+NKX+ cells in insulin-producing cells is not particularly limited, but can be preferably set to about 50% or less.

[0278] The ratio of Ins+NKX- cells in insulin-producing cells is preferably about 20% or more, more preferably about 25% or more, and even more preferably about 30% or more. In addition, the upper limit of the ratio of Ins+NKX- cells in insulin-producing cells is not particularly limited, but is preferably about 40% or less.

[0279] For example, the insulin-producing cells contain Ins+NKX+ cells at a ratio of about 30% to about 50% and below, and contain Ins+NKX- cells at a ratio of about more than 15% to about 40% or below, preferably at a ratio of about 20% to about 40% or below, more preferably at a ratio of about 25% to about 40% or below, and further preferably at a ratio of about 30% to about 40% or below.

[0280] In addition, in this specification, the ratio of cells specified in insulin-producing cells refers to the ratio relative to the total number of cells contained in insulin-producing cells. In addition, the ratio of each cell represents the value of insulin-producing cells induced to differentiate into islet-like cells (i.e., transplanted in vivo).

[0281] Ins+NKX- cells are commonly found in immature (early differentiation stage) insulin-producing cells, so the higher the proportion of Ins+NKX- cells, the more immature (early differentiation stage) insulin-producing cells they are.

[0282] The insulin-producing cells may further have one or more characteristics selected from the following a. to f.:

[0283] a. The expression level of MafA gene or its protein is low;

[0284] b. The proportion of Ki67-positive cells is low;

[0285] c. The proportion of glucagon-positive and insulin-negative cells was low;

[0286] d. Shows glucose-stimulated insulin secretion response;

[0287] e. A high proportion of chromogranin A-positive cells; and

[0288] f. The proportion of alkaline phosphatase-positive pluripotent stem cells is low.

[0289] Here, "plurality" means 2, 3, 4, 5 or 6.

[0290] a. The expression level of MafA gene or its gene product is low

[0291] The insulin-producing cells of the present invention are characterized in that the expression level of the MafA gene or the protein thereof is lower than the expression level of the MafA gene or the protein thereof in pancreatic islets.

[0292] "Pancreatic islets" refer to cells that are further differentiated than insulin-producing cells, and include mature pancreatic β cells, and are characterized by the expression of at least one of MafA, UCN3, and IAPP, which are markers for mature pancreatic β cells. Pancreatic islets can be isolated from healthy people.

[0293] The comparison of the expression level of the MafA gene or its protein between insulin-producing cells and pancreatic islets can be performed using techniques known in the art, for example, by using RT-PCR, microarray, biochip, Western blot, ELISA, immunostaining, flow cytometry and other techniques to detect / quantify the expression level of the MafA gene or its protein, and comparing the expression level with the relative value obtained by calibrating the expression level of the internal standard gene or its protein. The "internal standard gene" is not particularly limited, and can be, for example, GAPDH (glyceraldehyde-3-phosphate dehydrogenase), β-actin, β2-microglobulin, HPRT 1 (hypoxanthinephosphoribosyltransferase 1), etc.

[0294] The expression level of the MafA gene or its protein in insulin-producing cells is about 20% or less of the expression level of the MafA gene or its protein in pancreatic islets, preferably about 15% or less, more preferably about 10% or less, further preferably about 5% or less, and particularly preferably about 1% or less.

[0295] The MafA gene or its protein is a marker for mature pancreatic β cells, and thus this feature shows that the insulin-producing cells of the present invention are at a differentiation stage where they contain almost no mature pancreatic β cells or contain them at a low ratio.

[0296] b. The proportion of Ki67 positive cells is low

[0297] The insulin-producing cells of the present invention are characterized by containing Ki67-positive cells at a ratio of less than 3%.

[0298] "Ki67-positive cells" refer to highly proliferative cells characterized by Ki67 expression as a marker, which are mixed in insulin-producing cells differentiated and induced from pluripotent stem cells. "Ki67" is known to be a cell cycle-related nuclear protein, and its expression can be confirmed in the G1 phase, S phase, G2 phase, and M phase of proliferating cells, but its expression is not confirmed in the G0 phase where proliferation stops, so it is also known as a marker of cell proliferation and cell cycle.

[0299] Hereinafter, in this specification, "Ki67 positive" may be described as "Ki67+". In addition, "Ki67 positive cells" may be described as "Ki67+ cells".

[0300] The proportion of Ki67+ cells among insulin-producing cells is less than about 3%, less than about 1.5%, preferably less than about 1%, more preferably less than about 0.8%, and further preferably less than about 0.5%.

[0301] This feature shows that in the insulin-producing cells of the present invention, there is almost no or a low proportion of Ki67+ cells mixed in or remaining. Since Ki67+ cells have a high proliferation rate, they may have adverse effects on the recipient or affect the long-term engraftment of the transplanted cells, and there are cases where their mixing / remaining is not good.

[0302] c. The proportion of glucagon-positive and insulin-negative cells is low

[0303] The insulin-producing cells of the present invention are characterized in that they contain glucagon-positive and Ins- cells at a ratio of less than 3%. Hereinafter, in this specification, "glucagon-positive" may be described as "Gcg+". In addition, "glucagon-positive and insulin-negative cells" may be described as "Gcg+Ins- cells".

[0304] The ratio of Gcg+Ins- cells in insulin-producing cells is about 2.5% or less, preferably about 2% or less, more preferably about 1% or less, and further preferably about 0.5% or less.

[0305] Gcg+Ins- is a marker for mature pancreatic α cells, and this feature shows that the insulin-producing cells of the present invention are at a differentiation stage where they contain almost no mature pancreatic α cells or contain them at a low ratio.

[0306] d. Shows glucose-stimulated insulin secretion response

[0307] The insulin-producing cells of the present invention show glucose-stimulated insulin secretion (GSIS) response.

[0308] The GSIS response in insulin-producing cells can be performed according to previously known techniques (e.g., U.S. Application No. 11 / 773,944), for example, by measuring the amount of C-peptide secreted in the culture medium. C-peptide is a decomposition product produced in equimolar amounts relative to insulin during the maturation of proinsulin. The amount of C-peptide can be measured, for example, by ELISA using anti-C-peptide monoclonal antibodies.

[0309] e. The proportion of chromogranin A positive cells is high

[0310] The insulin-producing cells of the present invention are characterized in that they contain chromogranin A-positive cells at a ratio of about more than 45%.

[0311] Hereinafter, in this specification, "chromogranin A positive" may be described as "Chga+". Also, "chromogranin A positive cell" may be described as "Chga+ cell".

[0312] The ratio of Chga+ cells in insulin-producing cells is preferably about 50% or more (e.g., about 55% or more), more preferably about 60% or more, even more preferably about 70% or more, still more preferably about 80% or more, still preferably about 85% or more, and particularly preferably about 90% or more. The upper limit of the ratio of Chga+ cells in insulin-producing cells is not particularly limited, and can be, for example, about less than 95% or about less than 99%. The ratio of Chga+ cells in insulin-producing cells can also be about 93% or more.

[0313] Chga+ cells include cells that secrete hormones such as insulin (endocrine cells), and the above-mentioned Ins+NKX+ cells or Ins+NKX- cells are also included in them. Therefore, this feature shows that the insulin-producing cells of the present invention contain endocrine cells at a high ratio.

[0314] f. The proportion of alkaline phosphatase-positive pluripotent stem cells is low

[0315] The insulin-producing cells of the present invention are characterized by containing alkaline phosphatase-positive pluripotent stem cells at a ratio of less than about 0.01%.

[0316] The ratio of alkaline phosphatase-positive pluripotent stem cells in insulin-producing cells can be preferably set to about 0.008% or less, more preferably about 0.005% or less, and even more preferably about 0.001% or less.

[0317] Alkaline phosphatase is a marker showing the undifferentiated state of pluripotent stem cells. Therefore, this feature shows that the insulin-producing cells of the present invention contain almost no or a low proportion of non-target pluripotent stem cells that have not been induced to differentiate.

[0318] The alkaline phosphatase-positive pluripotent stem cells may further express other markers showing pluripotency. Other markers showing pluripotency of pluripotent stem cells may be selected from at least one of Nanog, Sox2, SSEA-1, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, etc.

[0319] Insulin producing cells of the present invention may also be in a state of cryopreservation. The cryopreserved insulin producing cells of the present invention are thawed and, like fresh insulin producing cells not cryopreserved, can be differentiated / matured into islet-like cells for hormone secretion. Cryopreservation and thawing may be performed by commonly used techniques in the field.

[0320] The insulin-producing cells of the present invention can be produced by the techniques described in detail below.

[0321] 3. Islet-like cells

[0322] In the present specification, "islet-like cells" refer to mature cells obtained by differentiation induction of the above-mentioned insulin-producing cells, and refer to cells characterized by expressing at least one marker of MafA, UCN3 and IAPP, which are maturation markers of pancreatic β cells, and expressing glucagon, which is a maturation marker of pancreatic α cells, similar to "pancreatic islets" obtained by pancreatic development in a living body.

[0323] More specifically, in this specification, "islet-like cells" may have one or more characteristics selected from the following (a) to (d):

[0324] (a) The proportion of chromogranin A-positive cells (Chga+ cells) was high;

[0325] (b) The proportion of Ki67-positive cells (Ki67+ cells) was low;

[0326] (c) a higher proportion of glucagon-positive and insulin-negative cells (Gcg+Ins- cells);

[0327] (d) It has the effect of secreting insulin in response to hypoglycemia.

[0328] Here, "plurality" means 2, 3 or 4.

[0329] The presence or absence of the characteristics (a) to (d) can be evaluated one week after differentiation induction of insulin-producing cells (e.g., after transplantation into a living body), preferably two weeks later, and the upper limit of this period is not particularly limited and can be set to within one year. In addition, the ratio of the specified cells in the islet-like cells refers to the ratio relative to the total number of cells in the cell mass derived from the transplant.

[0330] (a) The proportion of Chga+ cells is higher

[0331] The islet-like cells of the present invention are characterized in that they contain Chga+ cells at a ratio of about 50% or more. Preferably, the ratio of Chga+ cells in the islet-like cells is about 60% or more, more preferably about 70% or more, still more preferably about 90% or more, and particularly preferably about 95% or more (e.g., about 97% or more, about 98% or more).

[0332] Chga+ cells include cells that secrete hormones such as insulin and glucagon (endocrine cells), and this feature shows that islet-like cells contain endocrine cells at a high ratio.

[0333] (b) The proportion of Ki67+ cells is low

[0334] The islet-like cells of the present invention are characterized in that they contain Ki67-positive cells at a ratio of about less than 3%. Preferably, the ratio of Ki67-positive cells in the islet-like cells is about less than 1%, more preferably about less than 0.8%, and further preferably about less than 0.5%.

[0335] This characteristic shows that Ki67+ cells, which are poorly mixed / remaining in islet-like cells, are almost absent or present at a very low ratio.

[0336] (c) The proportion of Gcg+Ins- cells is high

[0337] The islet-like cells of the present invention are characterized in that they contain Gcg+Ins-cells at a ratio of about 10% or more. Preferably, the ratio of Gcg+Ins-cells in the islet-like cells is about 15% or more, more preferably about 20% or more, and even more preferably about 25% or more. The upper limit of the ratio of Gcg+Ins-cells in the islet-like cells is not particularly limited, and for example, it can be set to about 50% or less, preferably about 45% or less, and more preferably about 40% or less.

[0338] Gcg+Ins- is a marker for mature pancreatic α cells, and thus it is shown that islet-like cells contain mature pancreatic α cells at a higher ratio than insulin-producing cells, indicating that islet-like cells are at a more mature differentiation stage than insulin-producing cells.

[0339] (d) Has the effect of secreting insulin in response to hypoglycemia

[0340] The islet-like cells of the present invention are characterized in that they have an insulin secretion effect in response to hypoglycemia. "Insulin secretion effect in response to hypoglycemia" means that the amount of insulin secretion increases within 1 hour, within 2 hours, within 3 hours, within 4 hours or within 5 hours from the time of hypoglycemia. "Hypoglycemia" means when the glucose concentration in the blood or in the culture medium is about 70 mg / dL or less. The determination of the amount of insulin secretion can be carried out by any means known in the past, and is not particularly limited, but can also be carried out by measuring the amount of C-peptide in the blood or in the culture medium.

[0341] Generally, if hypoglycemia occurs in a living body, the secretion of glucagon and the like is promoted to increase the blood sugar level, while glucagon is antagonized to secrete insulin to control the blood sugar level. The islet-like cells of the present invention can similarly control the blood sugar level of hypoglycemia, and have the effect of promoting the increase of blood sugar level in response to hypoglycemia and antagonizing it to secrete insulin.

[0342] 4. Cell production method

[0343] The insulin-producing cells of the present invention can be obtained by differentiation induction of pluripotent stem cells. The differentiation induction from pluripotent stem cells to insulin-producing cells can be carried out using the following differentiation induction steps:

[0344] Step 1) Differentiating and inducing pluripotent stem cells into embryonic endoderm cells;

[0345] Step 2) inducing differentiation of embryonic endoderm cells into gastrointestinal cells;

[0346] Step 3) inducing differentiation from gastrointestinal cells into posterior foregut cells;

[0347] Step 4) inducing differentiation from posterior foregut cells into pancreatic progenitor cells;

[0348] Step 5) inducing differentiation from pancreatic precursor cells into endocrine precursor cells; and

[0349] Step 6) Inducing differentiation from endocrine precursor cells into insulin-producing cells.

[0350] Hereinafter, each step will be described, but induction of differentiation of each cell is not limited to these techniques.

[0351] Step 1) Differentiation into embryonic endoderm cells

[0352] Preferably, the pluripotent stem cells are cultured in a medium containing a low dose of Activin A to differentiate into embryonic endoderm cells.

[0353] The culture medium used in this step can be RPMI culture medium, MEM culture medium, iMEM culture medium, DMEM (Dulbecco's modified Eagle's medium) culture medium, improved MEM zinc option culture medium, improved (Improved) MEM / 1% B-27 supplement / penicillin streptomycin (Penisilin Streptomycin) culture medium, MCDB131 / 20mM glucose / NaHCO3 / FAF-BSA / ITS-X / Glutamax / ascorbic acid / penicillin streptomycin (Penisilin Streptomycin) culture medium and other basic culture media used for mammalian cell culture.

[0354] Activin A may be included in the culture medium at a low dose, for example, in an amount of 5 ng / mL to 100 ng / mL, preferably 5 ng / mL to 50 ng / mL, more preferably 5 ng / mL to 10 ng / mL.

[0355] The culture medium may further include ROCK inhibitors and GSK3β inhibitors.

[0356] The concentration of the GSK3β inhibitor in the culture medium is appropriately set depending on the type of GSK3β inhibitor used. For example, when CHIR is used as the GSK3β inhibitor, the concentration may be generally 2 μM to 5 μM, preferably 2 μM to 4 μM, and particularly preferably about 3 μM.

[0357] The concentration of the ROCK inhibitor in the medium is appropriately set depending on the type of ROCK inhibitor used. For example, when Y27632 is used as the ROCK inhibitor, the concentration is generally 5 μM to 20 μM, preferably 5 μM to 15 μM, and particularly preferably 10 μM.

[0358] Insulin may be further added to the culture medium. Insulin may be contained in the culture medium in an amount of 0.01 μM to 20 μM, preferably 0.1 μM to 10 μM, and more preferably 0.5 μM to 5 μM. The concentration of insulin in the culture medium may be the concentration of insulin contained in the added B-27 supplement, but is not limited thereto.

[0359] The number of cells at the start of culture was not particularly limited, but was 22,000 cells / cm 2 Up to 150,000 cells / cm 2 , preferably 22000 cells / cm 2 Up to 100,000 cells / cm 2 , more preferably 22000 cells / cm 2 Up to 80,000 cells / cm 2The culture time is 1 to 4 days, preferably 1 to 3 days, particularly preferably 3 days.

[0360] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 5%.

[0361] Alternatively, in the present invention, embryonic endoderm cells can be produced by first culturing pluripotent stem cells in a medium under conditions where insulin acts in the presence of a low dose of activin A, and then second culturing them in a medium under conditions where insulin does not act.

[0362] (1) First training

[0363] "Conditions under which insulin acts" refers to conditions under which insulin causes activation of the insulin signaling pathway in cells. In general, insulin binds to insulin receptors on the cell membrane surface, activates tyrosine kinases inside the receptors, and tyrosine phosphorylates the insulin receptor matrix protein family (IRS: IRS-1, 2, 3). In this specification, these series of reactions triggered by the binding of insulin to the insulin receptor are referred to as "activation of the insulin signaling pathway."

[0364] The conditions under which insulin acts include, for example, the presence of insulin in the culture medium. Insulin can be produced by a recombinant method or by solid phase synthesis as long as it can activate the insulin signal transduction pathway in pluripotent stem cells. Insulin can be derived from humans, non-human primates, pigs, cattle, horses, sheep, goats, llamas, dogs, cats, rabbits, mice, guinea pigs, etc., preferably human insulin.

[0365] In the present invention, as long as the activation of the insulin signaling pathway in pluripotent stem cells can be produced, insulin variants, insulin derivatives or insulin agonists can also be used as "insulin". "Insulin variants" include polypeptides consisting of an amino acid sequence in which 1 to 20, preferably 1 to 10, and more preferably 1 to 5 amino acids are deleted, substituted, added or inserted into the amino acid sequence of insulin and can produce activation of the insulin signaling pathway, or polypeptides consisting of an amino acid sequence having a sequence identity of 80% or more, more preferably 90% or more, more preferably 95% or more, and most preferably 99% or more with the amino acid sequence of insulin and can produce activation of the insulin signaling pathway. Comparison of amino acid sequences can be performed by known techniques, for example, using BLAST (Basic Local Alignment Search Tool at the National Center for Biological Information), etc., for example, with preset settings. "Insulin derivatives" refer to polypeptides or substances with the same effect that are composed of amino acid sequences in which some groups of amino acid residues of insulin or insulin variants are chemically substituted (e.g., α-methylated, α-hydroxylated), deleted (e.g., deaminated), or modified (e.g., N-methylated) and that can activate the insulin signal transduction pathway. "Insulin agonists" refer to polypeptides or substances with the same effect that can bind to insulin receptors and activate the insulin signal transduction pathway regardless of the structure of insulin.

[0366] The medium of the first culture may contain insulin in an amount of 0.01 μM to 20 μM, preferably 0.1 μM to 10 μM, and more preferably 0.5 μM to 5 μM. The concentration of insulin in the medium may be the concentration of insulin contained in the added B-27 supplement, but is not limited thereto.

[0367] The culture medium may further contain a ROCK inhibitor and / or a GSK3β inhibitor. The concentration of the ROCK inhibitor in the culture medium is appropriately set according to the type of ROCK inhibitor used. For example, when Y27632 is used as a ROCK inhibitor, the concentration is generally 5 μM to 20 μM, preferably 5 μM to 15 μM, and particularly preferably 10 μM. The concentration of the GSK3β inhibitor in the culture medium can be appropriately set according to the type of GSK3β inhibitor used. For example, when CHIR is used as a GSK3β inhibitor, the concentration can generally be set to 2 μM to 5 μM, preferably 2 μM to 4 μM, and particularly preferably about 3 μM.

[0368] The culture medium may further include one or more selected from the group consisting of pyruvate (sodium salt, etc.), L-alanyl-L-glutamine and glucose. Pyruvate can be included in the culture medium in an amount of 10 mg / L to 1000 mg / L, preferably 30 mg / L to 500 mg / L, more preferably 50 mg / L to 200 mg / L, and particularly preferably about 110 mg / L. L-alanyl-L-glutamine can be included in the culture medium in an amount of 50 mg / L to 2000 mg / L, preferably 100 mg / L to 1500 mg / L, more preferably 500 mg / L to 1000 mg / L, and particularly preferably about 860 mg / L. Glucose can be included in the culture medium in an amount of more than 15 mM, preferably 15 mM to 30 mM, more preferably 15 mM to 25 mM, and particularly preferably about 25 mM. The concentrations of pyruvate, L-alanyl-L-glutamine and glucose in the culture medium can be the concentrations of pyruvate, L-alanyl-L-glutamine and glucose contained in DMEM culture medium (DMEM, high concentration glucose, GlutaMAXTM, pyruvate (Thermo Fisher Scientific)) or other DMEM culture media, but are not limited thereto.

[0369] The culture medium may be based on the above-mentioned basic medium and supplemented with one or more of the above-mentioned components. The basic medium is preferably a DMEM medium, more preferably a DMEM medium containing pyruvate, L-alanyl-L-glutamine and glucose in the above-mentioned amounts.

[0370] The culture time period of the first culture can be selected from the range of 6 hours to 48 hours, preferably 12 hours to 24 hours. The culture temperature is not particularly limited, and is 30°C-40°C (for example, 37°C). In addition, the carbon dioxide concentration in the culture container is, for example, about 5%. The culture can be carried out by either two-dimensional culture or three-dimensional culture. There is no particular limitation on the number of cells at the start of the culture. If it is a two-dimensional culture, it can be 50,000 to 1,000,000 cells / cm 2 , preferably 150,000 to 300,000 cells / cm 2 , more preferably about 200,000 cells / cm 2 The number of cells at the start of culture is not particularly limited, but in the case of three-dimensional culture, it can be 10,000 to 1,000,000 cells / mL, preferably 100,000 to 500,000 cells / mL.

[0371] (2) Second training

[0372] "Conditions under which insulin does not act" refer to conditions under which activation of the insulin signaling pathway in cells caused by insulin does not occur. "No activation of the insulin signaling pathway in cells" not only means that activation of the insulin signaling pathway does not occur at all, but also refers to a situation in which only a slight activation of the degree to which a significant difference cannot be confirmed is produced compared to the activation of the insulin signaling pathway in the absence of insulin. Therefore, "conditions under which insulin does not act" include, for example: no insulin is contained in the culture medium, or, even when insulin is contained in the culture medium, the amount contained is such that only a slight activation of the degree to which a significant difference cannot be confirmed is produced. Or, it refers to a situation in which activation of the insulin signaling pathway is not produced by including an insulin signaling inhibitor together even when insulin is contained in the culture medium. "Insulin signaling inhibitor" refers to a component that can block the insulin signaling pathway at any position. Such insulin signaling inhibitors include: polypeptides or compounds that bind to or compete with insulin, insulin receptors, various proteins that act as signaling substances, and inhibit the interaction between molecules in which these factors participate. For example, such insulin signal inhibitors include LY294002 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one)] which competitively inhibits ATP binding to the catalytic subunit of PI3 kinase. Insulin signal inhibitors are not limited thereto, and antibodies or dominant negative variants thereof that bind to insulin, insulin receptors, and various proteins that act as signaling substances, as well as antisense oligonucleotides or siRNAs to mRNAs of insulin receptors or various proteins that act as signaling substances, can also be used as insulin signal inhibitors. Insulin signal inhibitors can be purchased commercially or synthesized according to known methods.

[0373] The culture medium may further contain a ROCK inhibitor and / or a GSK3β inhibitor. The amount of the ROCK inhibitor and / or the GSK3β inhibitor in the culture medium may be selected from the range described in the first culture, and may be the same as or different from that used in the first culture.

[0374] The culture medium may further contain one or more selected from the group consisting of pyruvate, L-alanyl-L-glutamine and glucose. The amounts of pyruvate, L-alanyl-L-glutamine and glucose in the culture medium may be selected from the ranges described in the first culture above, and may be the same as or different from those used in the first culture.

[0375] The culture medium used in the second culture can be based on the basic medium used for the culture of mammalian cells, with one or more of the above components added. The basic medium can be the same basic medium used in the first culture, or different. Preferably, it is DMEM culture medium, more preferably, DMEM culture medium containing pyruvate, L-alanyl-L-glutamine and glucose in the above amounts.

[0376] The culture time period of the second culture is at least 6 hours, preferably selected from the range of 6 hours to 72 hours, and more preferably 24 hours to 72 hours. The culture temperature is not particularly limited, and is 30°C-40°C (e.g., 37°C). The culture can be carried out by any of two-dimensional culture and three-dimensional culture. In addition, the carbon dioxide concentration in the culture container is, for example, about 5%.

[0377] The medium for the first culture and the second culture may contain the aforementioned low dose of activin A. The amounts of activin A contained in the medium for the first culture and the second culture may be the same or different.

[0378] Dimethyl sulfoxide may be further added to the medium for the first culture and the second culture.

[0379] By culturing pluripotent stem cells in the presence of a low dose of activin A, or by first culturing pluripotent stem cells in the presence of a low dose of activin A in a culture medium under conditions where insulin is acted on, and then culturing them in a second culture medium under conditions where insulin is not acted on, the proportion of endocrine cells obtained after step 6) can be increased.

[0380] Step 2) Differentiation into gastrointestinal cells

[0381] Furthermore, the embryonic endoderm cells obtained in step 1) are cultured in a medium containing growth factors to induce differentiation into gastrointestinal cells. The culture period is 2 to 8 days, preferably about 4 days.

[0382] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 5%.

[0383] The culture medium may be the basic culture medium for mammalian cell culture described in step 1). In addition to growth factors, serum replacements, vitamins, antibiotics, etc. may be appropriately added to the culture medium.

[0384] Preferably, EGF, KGF and FGF10 are used as the growth factor, more preferably, EGF and / or KGF are used as the growth factor, and further preferably, KGF is used as the growth factor.

[0385] The concentration of the growth factor in the culture medium is appropriately set depending on the type of growth factor used, but is generally about 0.1 nM to 1000 μM, preferably about 0.1 nM to 100 μM. When EGF is used, its concentration is about 5 ng / ml to 2000 ng / ml (i.e., about 0.8 nM to 320 nM), preferably about 5 ng / ml to 1000 ng / ml (i.e., about 0.8 nM to 160 nM), and more preferably about 10 ng / ml to 1000 ng / ml (i.e., about 1.6 nM to 160 nM). When FGF10 is used, its concentration is about 5 ng / ml to 2000 ng / ml (i.e., about 0.3 nM to 116 nM), preferably about 10 ng / ml to 1000 ng / ml (i.e., about 0.6 nM to 58 nM), more preferably about 10 ng / ml to 1000 ng / ml (i.e., about 0.6 nM to 58 nM). For example, when KGF is used as a growth factor, its concentration is generally 5 ng / mL to 150 ng / mL, preferably 30 ng / mL to 100 ng / mL, and particularly preferably about 50 ng / mL.

[0386] Step 3) Differentiation into posterior foregut cells

[0387] Further, the gastrointestinal cells obtained in step 2) are cultured in a culture medium containing growth factors, cyclopamine, noggin, etc. to induce differentiation into posterior foregut cells. The culture period is 1 to 5 days, preferably about 2 days.

[0388] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 5%.

[0389] The culture medium may be the basic culture medium for mammalian cell culture described in step 1). In addition to growth factors, serum replacements, vitamins, antibiotics, etc. may be appropriately added to the culture medium.

[0390] Preferably, EGF, KGF and FGF10 are used as the growth factor, more preferably, EGF and / or KGF are used as the growth factor, and further preferably, KGF is used as the growth factor.

[0391] The concentration of the growth factor in the culture medium is appropriately set depending on the type of growth factor used, but is generally about 0.1 nM to 1000 μM, preferably about 0.1 nM to 100 μM. When EGF is used, its concentration is about 5 ng / ml to 2000 ng / ml (i.e., about 0.8 nM to 320 nM), preferably about 5 ng / ml to 1000 ng / ml (i.e., about 0.8 nM to 160 nM), and more preferably about 10 ng / ml to 1000 ng / ml (i.e., about 1.6 nM to 160 nM). When FGF10 is used, its concentration is about 5 ng / ml to 2000 ng / ml (i.e., about 0.3 nM to 116 nM), preferably about 10 ng / ml to 1000 ng / ml (i.e., about 0.6 nM to 58 nM), more preferably about 10 ng / ml to 1000 ng / ml (i.e., about 0.6 nM to 58 nM). For example, when KGF is used as a growth factor, its concentration is generally 5 ng / mL to 150 ng / mL, preferably 30 ng / mL to 100 ng / mL, and particularly preferably about 50 ng / mL.

[0392] The concentration of cyclopamine in the medium is not particularly limited, but is usually 0.5 μM to 1.5 μM, preferably 0.3 μM to 1.0 μM, particularly preferably about 0.5 μM.

[0393] The concentration of noggin in the culture medium is not particularly limited, but is generally 10 ng / mL to 200 ng / mL, preferably 50 ng / mL to 150 ng / mL, particularly preferably about 100 ng / mL.

[0394] In addition, dimethyl sulfoxide and activin may be added to the culture medium.

[0395] Step 4) Differentiation into pancreatic progenitor cells

[0396] Further, the posterior foregut cells obtained in step 3) are cultured in a medium containing a factor having CDK8 / 19 inhibitory activity, preferably in a medium containing a factor having CDK8 / 19 inhibitory activity and a growth factor, to induce differentiation into pancreatic progenitor cells. The culture period is 2 to 10 days, preferably about 5 days.

[0397] The posterior foregut cells obtained in step 3) were prepared according to a previous report (Toyoda et al., Stem cell Research (2015) 14, 185 to 197). After being treated with 0.25% trypsin EDTA, the 0.25% trypsin EDTA was centrifuged and suspended by pipetting, and then re-inoculated into the fresh culture medium of step 4.

[0398] As the culture medium, a basic medium for culturing mammalian cells can be used as in step 1). In addition to growth factors, serum replacements, vitamins, antibiotics, etc. can be appropriately added to the culture medium.

[0399] The aforementioned various compounds or salts thereof can be used as factors having CDK8 / 19 inhibitory activity, and the amount added to the culture medium is appropriately determined according to the compound or salt used, usually about 0.00001 μM to 5 μM, preferably 0.00001 μM to 1 μM. The concentration of the factor having CDK8 / 19 inhibitory activity in the culture medium is preferably a concentration at which the inhibitory activity against CDK8 / 19 reaches 50% or more.

[0400] Preferably, EGF, KGF and FGF10 are used as growth factors, more preferably, KGF and / or EGF are used as growth factors, and further preferably, KGF and EGF are used as growth factors.

[0401] The concentration of the growth factor in the culture medium is appropriately set depending on the type of growth factor used, but is generally about 0.1 nM to 1000 μM, preferably about 0.1 nM to 100 μM. When EGF is used, its concentration is about 5 ng / ml to 2000 ng / ml (i.e., about 0.8 nM to 320 nM), preferably about 5 ng / ml to 1000 ng / ml (i.e., about 0.8 nM to 160 nM), and more preferably about 10 ng / ml to 1000 ng / ml (i.e., about 1.6 nM to 160 nM). When FGF10 is used, its concentration is about 5 ng / ml to 2000 ng / ml (i.e., about 0.3 nM to 116 nM), preferably about 10 ng / ml to 1000 ng / ml (i.e., about 0.6 nM to 58 nM), and more preferably about 10 ng / ml to 1000 ng / ml (i.e., about 0.6 nM to 58 nM). For example, when KGF and EGF are used as growth factors, the concentration of KGF is usually 5 ng / mL to 150 ng / mL, preferably 30 ng / mL to 100 ng / mL, and particularly preferably about 50 ng / mL; the concentration of EGF is usually 10 ng / mL to 200 ng / mL, preferably 50 ng / mL to 150 ng / mL, and particularly preferably about 100 ng / mL.

[0402] For the culturing in step 4), the first day may be performed in the presence of a ROCK inhibitor, and thereafter, the culturing may be performed in a medium not containing a ROCK inhibitor.

[0403] In addition, the culture medium may also contain a PKC activator. PdBU (PKC activator II), TPB (PKC activator V) and the like are used as PKC activators, but are not limited thereto. Activin A is added at a concentration of about 0.1 ng / ml to 100 ng / ml, preferably about 1 ng / ml to 50 ng / ml, and more preferably about 3 ng / ml to 10 ng / ml.

[0404] In addition, dimethyl sulfoxide and activin may be added to the culture medium.

[0405] In any step, in addition to the above-mentioned components, a serum replacement (e.g., B-27 supplement, ITS-G) may be added to the culture medium. In addition, amino acids, L-glutamine, GlutaMAX (product name), non-essential amino acids, vitamins, antibiotics (e.g., antibiotic-antimycin (referred to as AA in this specification), penicillin, streptomycin, or a mixture thereof), antibacterial agents (e.g., amphotericin B), antioxidants, pyruvic acid, buffers, inorganic salts, etc. may be added as needed. When the antibiotic is added to the culture medium, its concentration in the culture medium is generally 0.01% to 20% by weight, preferably 0.1% to 10% by weight.

[0406] In addition, feeder cells are not used, and cell culture is carried out by adhesion culture. During cultivation, culture vessels such as cell culture sheets of culture dishes, flasks, microplates, OptiCell (product name) (Nunc company) etc. are used. Preferably, the culture vessel is surface treated to improve its adhesion (hydrophilicity) to cells, and collagen, gelatin, poly-L-lysine, poly-D-lysine, laminin, fibronectin, matrigel (for example, BD matrigel (Becton Dickinson, Japan), vitronectin etc. are coated thereon with a matrix for cell adhesion. Preferably, a culture vessel coated with type I collagen, matrigel, fibronectin, vitronectin or poly-D-lysine etc. is used as a culture vessel, more preferably a culture vessel coated with matrigel or poly-D-lysine is used as a culture vessel.

[0407] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 5%.

[0408] Step 5) Differentiation into endocrine precursor cells

[0409] Furthermore, the pancreatic precursor cells obtained in step 4) are cultured in a medium containing growth factors to induce differentiation into endocrine precursor cells. The culture period is 2 to 3 days, preferably about 2 days.

[0410] The culture medium may use the basic culture medium for mammalian cell culture described in step 1). According to previous reports (Nature Biotechnology 2014; 32: 1121-1133), SANT1, retinoic acid, ALK5 inhibitor II, T3 and LDN are added to the culture medium. Furthermore, Wnt inhibitors, ROCK inhibitors, FGF (preferably FGF2), serum replacements, vitamins, antibiotics, etc. may also be appropriately added to the culture medium. In addition, dimethyl sulfoxide and activin may also be added to the culture medium.

[0411] In addition, the cells are cultured by non-adhesive culture without using feeder cells. During the culture, a culture dish, flask, microplate, multi-well plate (Nunc) or the like or a bioreactor is used. The culture container is preferably surface treated to reduce its adhesion to the cells.

[0412] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 5%.

[0413] Step 6) Differentiation into insulin-producing cells

[0414] Furthermore, the endocrine precursor cells obtained in step 5) are cultured in a medium containing an FGFR1 inhibitor to induce differentiation into insulin-producing cells. The culture period is 14 to 30 days, preferably about 14 to 20 days.

[0415] The culture medium may use the basic culture medium for mammalian cell culture described in step 1). According to previous reports (Nature Biotechnology 2014; 32: 1121-1133), ALK5 inhibitor II, T3, LDN, γ-secretase inhibitor XX, γ-secretase inhibitor RO, N-cysteine, AXL inhibitor, ascorbic acid are added to the culture medium. Furthermore, Wnt inhibitors, ROCK inhibitors, FGF (preferably FGF2), serum replacements, vitamins, antibiotics, etc. may be appropriately added to the culture medium. For example, ALK5 inhibitor II, T3, LDN, γ-secretase inhibitor RO and ascorbic acid may be added to the culture medium, or T3, ALK5 inhibitor II, ZnS04, heparin, N-acetylcysteine, Trolox and R428 may also be added.

[0416] In addition, the cells are cultured by non-adhesive culture without using feeder cells. During the culture, a culture dish, flask, microplate, multi-well plate (Nunc) or the like or a bioreactor is used. The culture container is preferably surface treated to reduce its adhesion to the cells.

[0417] The culture temperature is not particularly limited, but is 30° C. to 40° C. (eg, 37° C.) The carbon dioxide concentration in the culture container is, for example, about 1.5 Å.

[0418] In the culture medium, the FGFR1 inhibitor may be included in any amount capable of inhibiting the activity of FGFR1, for example, in an amount of less than 10 μM or less than 5 μM, preferably less than 5 μM, less than 4 μM, less than 3 μM, or less than 2 μM. The lower limit of the amount of the FGFR1 inhibitor added is not particularly limited, and may be set to be 0.1 μM or more, preferably 0.5 μM or more. The amount of the FGFR1 inhibitor added is preferably less than 5 μM and 0.1 μM or more, more preferably less than 5 μM and 0.5 μM or more. Cultivation in the presence of the FGFR1 inhibitor may be performed for at least 12 hours, preferably more than 24 hours, more than 2 days, more than 4 days, more than 8 days, more than 10 days, or more than 15 days. Cultivation in the presence of the FGFR1 inhibitor is preferably performed for more than 4 days. For example, cultivation in the presence of the FGFR1 inhibitor may be performed for the last about 4 to 15 days of step 6), preferably the last about 4 to 7 days. The culture medium may be replaced with the FGFR1 inhibitor during the treatment, and may be replaced with a culture medium having the same composition as before the addition of the replacement for the FGFR1 inhibitor or with a culture medium having a different composition according to the culture schedule.

[0419] By culturing the cells in a medium containing a FGFR1 inhibitor, the proliferation of Ki67-positive cells among the resulting insulin-producing cells can be suppressed.

[0420] The insulin-producing cells obtained in step 6) may be cryopreserved until use.

[0421] 5. Differentiation into islet-like cells

[0422] The insulin-producing cells of the present invention can be induced to differentiate into islet-like cells by being transplanted into a living animal.

[0423] The "animal" is preferably a mammal, and examples thereof include humans, non-human primates, pigs, cattle, horses, sheep, goats, llamas, dogs, cats, rabbits, mice, guinea pigs, etc., and preferably humans.

[0424] Transplantation is preferably performed in a living region where the cells can be fixed at a certain position, for example, it can be performed subcutaneously, intraperitoneally, under the capsule of the peritoneal epithelium, omentum, adipose tissue, muscle tissue, pancreas, kidney, etc. The number of transplanted cells can vary depending on factors such as the age, weight, and size of the transplanted site of the transplanted subject, and is not particularly limited. For example, it can be 10×10 4 cells to 10×10 11The number of cells transplanted can be induced to differentiate into islet-like cells in the living body environment. In addition, the number of cells transplanted can vary according to factors such as the age, weight, and transplantation site of the transplanted object. After 1 week, preferably 2 weeks after transplantation, the transplanted insulin-producing cells differentiate / mature into islet-like cells. The obtained islet-like cells can be recovered later or directly left in the living body.

[0425] 6. Purpose

[0426] The insulin-producing cells of the present invention can be prepared as a medicine directly or by mixing with a pharmacologically acceptable carrier or the like, and thus can be safely administered to a patient in need thereof.

[0427] The "pharmacologically acceptable carrier" can be transplanted into the living body together with the insulin-producing cells, and the transplanted insulin-producing cells can differentiate / mature into islet-like cells. Any carrier obtained according to the desired dosage form can be appropriately used. For example, an example of a "pharmacologically acceptable carrier" is a hydrogel. The hydrogel is preferably composed of a polymer that is compatible with the living body and / or biodegradable. Such a hydrogel can be composed of one or more selected from the group consisting of alginate, fibronectin, gelatin, collagen, proteoglycan, glucosamine polysaccharide (e.g., hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, keratan sulfate, etc.), laminin, vitronectin, and salts or esters thereof. For example, a gel containing alginic acid prepared using alginate (e.g., sodium alginate, calcium alginate, ammonium alginate, etc.) or alginate ester (also known as propylene glycol alginate) (WO 2010 / 032242, WO 2011 / 154941) can be suitably used as the hydrogel. The hydrogel can be used by dispersing insulin-producing cells in the gel.

[0428] In addition, insulin-producing cells or drugs may also be contained in an apparatus that can accommodate them. The apparatus may be composed of any shape and material, as long as it can be transplanted into the living body together with the insulin-producing cells or drugs, and the transplanted insulin-producing cells can differentiate / mature into islet-like cells. For example, examples of such apparatuses may be composed of living body-compatible and / or biodegradable polymers (e.g., polyglycolic acid, polylactic acid, etc.), ceramics, metals (e.g., titanium, stainless steel, cobalt or their alloys, etc.). The shape of the apparatus is not particularly limited, and can be set to the shape of a capsule, bag, chamber, etc. that can accommodate insulin-producing cells or drugs. The apparatus preferably has a porous portion, hole, passage, etc. that can connect its interior and exterior.

[0429] The insulin-producing cells or drugs of the present invention can be supplied in a frozen state and can be thawed before use.

[0430] The insulin-producing cells or drugs of the present invention can be transplanted into the living body of a patient in need thereof for use. Transplantation is preferably performed in a region in the living body where the cells can be fixed in a certain position, for example, subcutaneously, intraperitoneally, under the capsule of the peritoneal epithelium, omentum, adipose tissue, muscle tissue, pancreas, kidney, and other organs. Subcutaneous transplantation with a low degree of invasiveness is preferred. The transplanted insulin-producing cells only need to be administered in a therapeutically effective amount, which can vary depending on factors such as the age, weight, size of the transplant site, and severity of the disease of the transplantee, and is not particularly limited. For example, it can be set to 10×10 4 cells to 10×10 11 About cells.

[0431] The transplanted insulin-producing cells differentiate and mature in vivo to become pancreatic islet-like cells, and exert functions useful for treating or preventing diseases, disorders or symptoms. That is, the insulin-producing cells or drugs of the present invention can be used as prodrugs.

[0432] The insulin-producing cells or drugs according to the present invention can produce islet-like cells in the patient's living body, and the blood sugar (glucose) level in the patient can be improved and / or maintained through the action of insulin or glucagon secreted by the islet-like cells.

[0433] Therefore, the insulin-producing cells or drugs of the present invention can be used to treat or prevent diseases, disorders or symptoms that need to improve and / or maintain the level of blood sugar levels. Such diseases, disorders or symptoms include diabetes in patients, especially diabetics, abnormal fasting and postprandial glucose levels, hypoglycemia (for example, hypoglycemia caused by insulin administration in diabetics), etc., but are not limited to this. In addition, "treatment" refers to the treatment, cure, prevention or alleviation of a disease, disorder or symptom, or a reduction in the rate of progression of a disease, disorder or symptom. In addition, "prevention" refers to reducing the possibility and risk of the onset of a disease, disorder or symptom, or delaying the onset of a disease, disorder or symptom.

[0434] The patient is a mammal (eg, mouse, rat, hamster, rabbit, cat, dog, cow, sheep, monkey, human), preferably a human.

[0435] Hereinafter, the present invention will be described by way of examples, but the present invention is not limited to these examples.

[0436] Example

[0437] Example 1: Maturity of insulin-producing cells and the rate of incorporation of proliferative cells

[0438] 1. Methods

[0439] (1) Preparation of insulin-producing cells

[0440] Induction of differentiation from the Ff-I14s04 iPS cell line into insulin-producing cells was performed according to the above steps 1) to 6) and a previous report (Nature Biotechnology 2014; 32: 1121-1133).

[0441] That is, iPS cells were suspended in an iPS cell culture medium containing 10 μM of ROCK inhibitor (Y-27632) and counted using a cell counter NC200 (ChemoMetec) to adjust the cell count to 37.5×10 4 cells / mL, 2mL / well (75×10 4 Cells / well) are inoculated onto a plate coated with iMatrix and incubated. Then, under the condition of insulin action, a first culture is performed in a medium (DMEM-high glucose-GlutaMAX-pyruvate / 2% B27 (containing insulin) / penicillin-streptomycin / 1% dimethyl sulfoxide) containing differentiation-inducing factors (GSK3β inhibitor (3 μM CHIR99021), low dose (10 ng / mL) activin A), and then a second culture is performed under the condition of insulin inaction, i.e., in a medium (DMEM-high glucose-GlutaMAX-pyruvate / 2% B27 (without insulin) / penicillin-streptomycin / 1% dimethyl sulfoxide) containing differentiation-inducing factors (low dose (10 ng / mL activin A)) to obtain embryonic endoderm cells. The obtained embryonic endoderm cells are placed in a culture medium containing 50 ng / mL of KGF (modified MEM / 1% B27 (containing insulin) / penicillin-streptomycin);

[0442] Then, the posterior foregut cells obtained by culturing in a medium (modified MEM / 1% B27 (containing insulin) / penicillin-streptomycin) containing 50 ng / mL KGF, 100 ng / mL noggin, 0.5 μM cyclopamine, 10 nM TTNPB, and 250 μM vitamin C were recovered;

[0443] The cells were suspended in a culture medium (modified MEM / 1% B27 (with insulin) / penicillin-streptomycin) containing 0.1 μM ROCK inhibitor, 100 ng / mL KGF, 50 ng / mL EGF, 10 mM nicotinamide, and 250 μM vitamin C, and the concentration was adjusted to 175×10 4 cells / mL; 350×10 4 The cells / well were then seeded onto iMatrix-coated plates for culture.

[0444] The obtained cells were recovered again and suspended in a culture medium (modified MEM / 1% B27 (containing insulin) / penisilin streptomycin) containing 0.25 μM SANT-1, 50 nM retinoic acid, 10 μM ALK5 inhibitor II, 100 nM LDN, 1 μM T3, 50 ng / mL bFGF, 1 μM XAV, and 10 μM Y-27632, and the concentration was adjusted to 20×10 4 cells / mL, 3×10 4 Cells / well, and then inoculated into a cell non-adherent 96-well plate (Sumitomo Bakelite) for culture. The obtained cell population was cultured in a culture medium (modified MEM / 1% B27 (containing insulin) / penicillin-streptomycin) containing 10 μM ALK5 inhibitor II, 1 μM T3, 100 μM LDN, 1 μM γ-secretase inhibitor (RO-4929097), 250 μM ascorbic acid and 1 μM FGF receptor 1 inhibitor (PD-1666866) to obtain insulin-producing cells.

[0445] (2) Evaluation of protein expression

[0446] Protein expression (insulin (INS), NKX6.1, glucagon (GCG), Ki67) of insulin-producing cells prepared from Ff-I14s04 iPS cell line and human pancreatic islets isolated from healthy individuals (hereinafter referred to as "islets") was measured by flow cytometry. In addition, as a control, a prototype of insulin-producing cells prepared without treatment with FGF receptor 1 inhibitor (PD-166866) (hereinafter referred to as "prototype") was also measured in the same manner.

[0447] (3) Evaluation of gene expression

[0448] Using cDNA synthesized from total RNA fractions of each sample taken from prototype, insulin-producing cells and islets, the mRNA expression levels of MafA and UCN3, known as markers of insulin, glucagon and mature pancreatic β cells, were measured by quantitative PCR. The expression level of GAPDH mRNA was measured in the same manner as the control gene for normalization.

[0449] 2. Results

[0450] (1) Evaluation of protein expression

[0451] The results of flow cytometry are shown in Figure 1. In addition, the insulin-positive / NKX6.1-positive cell rate, the insulin-positive / NKX6.1-negative cell rate, the chromogranin A-positive cell rate, and the Ki67-positive cell rate are shown in Table 1. Insulin-producing cells show an insulin-positive / NKX6.1-positive cell rate that is equal to or higher than that of pancreatic islets. On the other hand, with respect to the insulin-positive / NKX6.1-negative cell rate, it can be confirmed that the insulin-producing cells are significantly higher than those of pancreatic islets. If the insulin-producing cells are compared with the prototype, in the insulin-producing cells, the insulin-positive / NKX6.1-positive cell rate, the insulin-positive / NKX6.1-negative cell rate, and the chromogranin A-positive cell rate increase, while the Ki67-positive cell rate decreases significantly.

[0452] [Table 1]

[0453]

[0454] nd, not determined

[0455] (2) Evaluation of gene expression

[0456] The expression levels of insulin, glucagon, MafA and UCN3 in prototype, insulin-producing cells and pancreatic islets are shown in Table 2 and Figure 2 .

[0457] Consistent with the results of insulin-positive cell rate and glucagon-positive cell rate obtained by flow cytometry, the expression of insulin and glucagon in insulin-producing cells increased compared with the prototype, reaching a level of about 50% of that in pancreatic islets. On the other hand, it was found that the expression levels of MafA and UCN3 in insulin-producing cells were extremely low compared with those in human pancreatic islets.

[0458] [Table 2.]

[0459]

[0460] These results show that insulin-producing cells are cell aggregates containing β cells at a ratio similar to that of pancreatic islets, but are not immature pancreatic islets. In addition, it was confirmed that insulin-producing cells were rarely mixed with proliferative non-target cells (Ki67-positive cells).

[0461] Example 2: Incorporation rate of iPS cells maintained in an undifferentiated state into insulin-producing cells

[0462] 1. Methods

[0463] High efficient culture cell assay for maintaining iPS cells in an undifferentiated state

[0464] Ff-I14s04 iPS cells were cultured in a medium (RPMI / 1% B27 (containing insulin) / penicillin-streptomycin / dimethyl sulfoxide) containing differentiation inducing factors (GSK3β inhibitor, ROCK inhibitor and low dose of activin A), and the obtained embryonic endoderm cells were differentiated into pancreatic progenitor cells (intermediate cells in the process of insulin-producing cell production) at 6×10 5 0, 6 (0.001%), and 30 (0.005%) iPS cells were added to a suspension of pancreatic progenitor cells of 100 cells each, seeded on a 10 cm culture dish, and cultured for 7 days in AK03N medium and iMatrix-511 coating conditions, which are favorable conditions for maintaining undifferentiated iPS cells. In addition, 6×10 cells without iPS cells were cultured under the same conditions. 5 After the culture was completed, the colonies of iPS cells that maintained an undifferentiated state were visualized and counted by alkaline phosphatase staining.

[0465] 2. Results

[0466] The results are shown in Figure 3 . In the pancreatic progenitor cell culture dishes mixed with 6 cells and 30 cells of iPS cells maintained in an undifferentiated state, an average of 3 and 16 colonies were observed, respectively. On the other hand, no colonies were observed in the pancreatic progenitor cell culture dishes without the addition of iPS cells. The above results show that the contamination of iPS cells maintained in an undifferentiated state in the pancreatic progenitor cells produced by the current differentiation induction method and the insulin-producing cells produced subsequently is less than 0.001%.

[0467] The above results confirmed that there were no or very few iPS cells maintained in an undifferentiated state mixed in the insulin-producing cells.

[0468] Example 3: Effects of freeze-thaw on insulin-producing cells

[0469] 1. Methods

[0470] (1) Reaggregation of insulin-producing cells after freezing and thawing

[0471] In addition to culturing Ff-I14s04 iPS cells in a medium (RPMI / 1% B27 (containing insulin) / penicillin-streptomycin / dimethyl sulfoxide) containing differentiation inducing factors (GSK3β inhibitor, ROCK inhibitor and low dose of activin A) to obtain embryonic endoderm cells, insulin-producing cells were prepared by the same method as described in Example 1 and frozen by slow freezing using a commercially available cryopreservation solution (CryoStor CS10 (BioLifeSolutions)). Specifically, 3×10 6 Each cell was suspended in 1 mL of cryopreservation solution and injected into a cryovial. The vial was placed in a cryoprocessing container (Buysell, Nippon Freezer Co., Ltd.) and stored at -80°C.

[0472] Thawing is to heat and thaw the frozen vial quickly on the ThawSTAR frozen cell thawing station (Astero Bio). The thawed cell suspension is added to 10mL of culture medium. After removing the supernatant by centrifugation, the cells are suspended in a culture medium containing 10μM ROCK inhibitor (Y-27632), and the number of live cells and cell survival rate after thawing are measured using a cell counting device NC200 (ChemoMetec). In addition, the thawed cells are inoculated into a multi-well plate (Kuraray) and cultured in three dimensions to prepare cell aggregates.

[0473] (2) In vivo transplantation of insulin-producing cells after freeze-thaw

[0474] After freeze-thaw, the insulin-producing cells were transplanted into the renal capsule of immunodeficient NOD / SCID mice induced with insulin-deficient diabetes mellitus by streptozotocin. The post-transplantation process was observed and the blood human C-peptide concentration and blood glucose level were measured.

[0475] 2. Results

[0476] (1) Reaggregation of insulin-producing cells after freezing and thawing

[0477] The cell survival rate immediately after thawing was 80.9%. In addition, 77.0% of the live cells injected into the cryovial were recovered. Phase contrast microscopy images of cells obtained by culturing for 4 days in three-dimensional culture are shown in Figure 4 .like Figure 4 As shown, it is clear that the cells that were cryopreserved survived and maintained the ability to form cell aggregates.

[0478] The results of flow cytometry analysis of the expression of INS, NKX6.1, and Ki67 in cells before cryopreservation and after thawing / reculture are shown in Figure 5 In addition, the insulin positive rate and Ki67 positive cell rate are shown in Table 3. Figure 5 As shown in Table 3, the rate of insulin-positive cells did not decrease and the rate of Ki67-positive cells did not increase before / after cryopreservation.

[0479] [Table 3]

[0480] Before cryopreservation After thawing / re-culturing Insulin positive cell rate 52.7% 85.7% Ki67 positive cell rate 1.3% 0.3%

[0481] (2) In vivo transplantation of insulin-producing cells

[0482] The results of the measurement of blood human C-peptide concentration and blood sugar level after transplantation are shown in Table 4. The secretion of human C-peptide was confirmed in the blood of the frozen-thawed insulin-producing cells transplanted under the renal capsule 4 months after transplantation, indicating an effect of improving hyperglycemia.

[0483] [Table 4]

[0484]

[0485] From the above results, it was confirmed that the differentiation induction efficiency of insulin-producing cells was maintained even after freezing and thawing.

[0486] Example 4: Insulin-producing cells transplanted into living bodies

[0487] 1. Methods

[0488] (1) Transplantation of insulin-producing cells into living bodies

[0489] The insulin-producing cells prepared by the same method as in Example 3 were transplanted into the subrenal capsule of immunocompromised NOD / SCID mice with diabetes induced by streptozotocin (STZ) and into the subcutaneous tissue of naturally diabetic NOD / SCID mice with Akita gene mutation. Fibrin gel was used as a carrier of insulin-producing cells in the subcutaneous transplantation. After the transplantation, the concentration of human C-peptide (an indicator of insulin derived from insulin-producing cells) and blood glucose level in the blood were measured to evaluate the engraftment of insulin-producing cells.

[0490] (2) Evaluation of the response of insulin-producing cells to glucose load or hypoglycemia

[0491] Using mice transplanted with insulin-producing cells, glucose was orally administered to temporarily increase blood sugar levels, or insulin glargine was subcutaneously administered to induce hypoglycemia, and the blood human C-peptide concentration and blood glucagon concentration were measured to evaluate the response of the subsequent insulin-producing cells. Using non-transplanted / non-diabetic NOD / SCID mice as controls, the blood concentrations of mouse C-peptide or glucagon derived from endogenous pancreatic islets were measured.

[0492] 2. Results

[0493] (1) Evaluation of engraftment of insulin-producing cells transplanted into living bodies

[0494] The results of the measurement of the human C-peptide concentration and blood glucose level in the blood after transplantation are shown in Table 5. Human C-peptide was detected in the blood 3-4 months after transplantation in all animals and transplantation sites. In mice, hyperglycemia was improved 3 months after transplantation, and blood glucose levels were maintained at normal levels until 5-6 months after transplantation, indicating that the transplanted insulin-producing cells had long-term engraftment.

[0495] [Table 5]

[0496]

[0497] N=3 or more for mean ± standard deviation, N=2 for individual data

[0498] (2) Evaluation of the response of insulin-producing cells to glucose load or hypoglycemia

[0499] The concentration of human C-peptide in blood after glucose loading is shown in Figure 6 The blood human C-peptide concentration and blood glucagon concentration after administration of insulin glargine are shown in Figure 7 . 3-4.5 months after transplantation of insulin-producing cells, the concentration of human C-peptide in the blood temporarily increased due to glucose load, but on the other hand, it decreased when hypoglycemia was induced by administration of insulin glargine. These changes were the same as the changes in the blood concentration of endogenous mouse C-peptide in non-transplanted / non-diabetic mice. In addition, in mice transplanted with insulin-producing cells, the concentration of glucagon in the blood showed a higher value compared with non-transplanted / non-diabetic mice, indicating that insulin-producing cells release glucagon into the blood.

[0500] The above results indicate that insulin-producing cells transplanted into living bodies can remain engrafted for a long time and respond to fluctuations in blood glucose levels, exerting physiological insulin-regulating effects similar to endogenous pancreatic islets.

[0501] Example 5: Subcutaneous transplantation of insulin-producing cells

[0502] 1. Methods

[0503] (1) In vivo transplantation of insulin-producing cells

[0504] Insulin-producing cells dispersed in hydrogel alginate were subcutaneously transplanted into immunodeficient NOD / SCID mice with insulin-deficient diabetes induced by streptozotocin. The post-transplant process was observed by measuring the human C-peptide concentration and blood glucose level in the blood. The transplant was removed 3 months after transplantation.

[0505] (2) Evaluation of protein expression in transplants

[0506] The removed grafts were treated for single cells and fixed, and the protein expression of insulin-producing cells (insulin, NKX6.1, glucagon, chromogranin A) was measured by flow cytometry. In addition, the removed grafts and insulin-producing cells at the time of transplantation were fixed, dehydrated, and frozen sections were prepared, and the expression of target proteins (insulin, glucagon) was evaluated by immunohistochemical staining.

[0507] 2. Results

[0508] (1) In vivo transplantation of insulin-producing cells

[0509] The results of the measurement of blood human C-peptide concentration and blood sugar level during observation after transplantation are shown in Table 6. The secretion of human C-peptide was confirmed in 1 to 3 months after the subcutaneously transplanted insulin-producing cells, indicating an effect of improving hyperglycemia.

[0510] [Table 6]

[0511]

[0512] (2) Evaluation of protein expression in transplants

[0513] The results of the determination of the insulin-positive / NKX6.1-positive cell rate, the insulin-positive / NKX6.1-negative cell rate, the glucagon-positive / insulin-negative cell rate, and the chromogranin A-positive rate are shown in Table 7. Figure 8 Compared with the time of transplantation, an increase in the ratio of glucagon-positive / insulin-negative cells and a decrease in the ratio of insulin-positive / NKX6.1-negative cells were observed in the transplanted pieces 3 months after transplantation. In addition, it was confirmed that the transplanted pieces 3 months after transplantation were composed of a higher proportion of chromogranin A-positive endocrine cells. The results of immunohistochemical staining of the transplanted pieces are shown in Fig. 9 An increase in the rate of glucagon-positive cells was observed in the transplanted pieces 3 months after transplantation compared to the time of transplantation, indicating that the cells differentiated into mature islet-like cells in vivo.

[0514] [Table 7]

[0515]

[0516] The above results confirmed that the insulin-producing cells transplanted subcutaneously into diabetic mice maintained a high ratio of endocrine cells and differentiated into mature islet-like cells including mature α cells in vivo.

[0517] Furthermore, it was confirmed that mature islet-like cells in vivo contain very few (eg, less than 3%) proliferative non-target cells (Ki67-positive cells).

Claims

1. An insulin-producing cell, comprising more than 30% of insulin-positive and NKX6.1-positive cells, more than 15% of insulin-positive and NKX6.1-negative cells; less than 3% of Ki67-positive cells; and more than 85% of chromogranin A-positive cells.

2. The insulin-producing cell according to claim 1, wherein The expression level of the MafA gene or its gene product is lower than the expression level of the MafA gene or its gene product in pancreatic islets. 3 . The insulin-producing cell according to claim 1 , comprising glucagon-positive and insulin-negative cells at a ratio of less than 3%. The insulin-producing cell according to claim 1 , which exhibits a glucose-stimulated insulin secretion (GSIS) response. The insulin-producing cell according to claim 1 , comprising alkaline phosphatase-positive pluripotent stem cells at a ratio of less than 0.01%. 6 . A medicament comprising the insulin-producing cell according to any one of claims 1 to 5 .

7. The drug according to claim 6, wherein The insulin-producing cells are housed in a device.

8. The drug according to claim 6, wherein The insulin-producing cells are dispersed in the hydrogel.

9. Use of the insulin-producing cell according to any one of claims 1 to 5 in the preparation of a medicament for diabetes.

10. Use of the insulin-producing cell according to any one of claims 1 to 5 for the preparation of a medicament for improving and / or maintaining the control of fasting and postprandial glucose levels in patients suffering from diabetes.

11. Use of an insulin producing cell according to any one of claims 1 to 5 for the preparation of a medicament for reducing the risk of hypoglycemia in a diabetic patient.

12. Use of the insulin-producing cell according to any one of claims 1 to 5 for preparing a medicament for inducing differentiation into islet-like cells in vivo.

13. The use according to claim 12, wherein The islet-like cells differentiated in vivo contain chromogranin A-positive cells at a ratio of 50% or more.

14. The use according to claim 12, wherein The islet-like cells differentiated in vivo contain Ki67-positive cells at a ratio of less than 3%.

15. The use according to claim 12, wherein The islet-like cells differentiated in vivo contain glucagon-positive and insulin-negative cells at a ratio of 10% or more.

16. The use according to claim 12, wherein The islet-like cells differentiated in vivo have an effect of secreting insulin in response to hypoglycemia.

17. A method for producing insulin-producing cells, wherein: The insulin-producing cells contain more than 30% insulin-positive and NKX6.1-positive cells, more than 15% insulin-positive and NKX6.1-negative cells, less than 3% Ki67-positive cells, and more than 85% chromogranin A-positive cells. The method for producing the insulin-producing cells comprises the following steps: a step of culturing pluripotent stem cells in the presence of 5 to 10 ng / mL of activin A to produce embryonic endoderm cells; and The step of culturing endocrine precursor cells in a medium containing 10 μM or less of a FGFR1 inhibitor to produce the insulin-producing cells.